Document:

Exhibit 10.2

 

CORPORATE INTEGRITY AGREEMENT

BETWEEN THE

OFFICE OF INSPECTOR GENERAL

OF THE

DEPARTMENT OF HEALTH AND HUMAN SERVICES

AND

21ST CENTURY ONCOLOGY, LLC

 

I.                                        PREAMBLE

 

21st Century Oncology, LLC (21st Century) hereby enters into this Corporate Integrity Agreement (CIA) with the Office of Inspector General (OIG) of the United States Department of Health and Human Services (HHS) to promote compliance with the statutes, regulations, and written directives of Medicare, Medicaid, and all other Federal health care programs (as defined in 42 U.S.C. § 1320a-7b(f)) (Federal health care program requirements). Contemporaneously with this CIA, 21st Century is entering into a Settlement Agreement with the United States.

 

21st Century represents that, prior to this CIA, 21st Century voluntarily established a Compliance Program which provides for a Corporate Compliance and Privacy Officer, a Compliance Committee, a compliance training and education program, a confidential disclosure reporting hotline, auditing and monitoring activities, and various policies and procedures aimed at ensuring that 21st Century’s participation in the federal health care programs conforms to all Federal and state laws and Federal health care program requirements. 21st Century shall continue its Compliance Program throughout the term of this CIA and shall do so in accordance with the terms set forth below. 21st Century may modify its Compliance Program, as appropriate, but at a minimum, 21st Century shall ensure that during the term of this CIA, it shall comply with the obligations set forth herein.

 

II.                                   TERM AND SCOPE OF THE CIA

 

A.                                    The period of the compliance obligations assumed by 21st Century under this CIA shall be five years from the effective date of this CIA. The “Effective Date” shall be the date on which the final signatory of this CIA executes this CIA. Each one-year period, beginning with the one-year period following the Effective Date, shall be referred to as a “Reporting Period.”

 

1

 

B.                                    Sections VII, X, and XI shall expire no later than 120 days after OIG’s receipt of: (1) 21st Century’s final annual report; or (2) any additional materials submitted by 21st Century pursuant to OIG’s request, whichever is later.

 

C.                                    The scope of this CIA shall be governed by the following definitions:

 

1.                                      “Covered Persons” includes:

 

a.                                      all owners, officers, directors, and employees of 21st Century; and

 

b.                                      all contractors, subcontractors, agents, and other persons who furnish patient care items or services or who perform billing or coding functions on behalf of 21st Century, excluding vendors whose sole connection with 21st Century is selling or otherwise providing medical supplies or equipment to 21st Century.

 

Notwithstanding the above, this term does not include part-time or per diem employees, contractors, subcontractors, agents, and other persons who are not reasonably expected to work more than 160 hours during a Reporting Period, except that any such individuals shall become “Covered Persons” at the point when they work more than 160 hours during a Reporting Period.

 

2.                                      “Relevant Covered Persons” includes Covered Persons involved in the delivery of patient care items or services and/or in the preparation or submission of claims for reimbursement from any Federal health care program.

 

III.                              CORPORATE INTEGRITY OBLIGATIONS

 

21st Century shall continue to maintain a Compliance Program that includes the following elements:

 

A.                                    Chief Compliance Officer and Committee

 

1.                                      Chief Compliance Officer. Within 90 days after the Effective Date, 21st Century shall appoint a Chief Compliance Officer and shall maintain a Chief Compliance Officer for the term of the CIA. The Chief Compliance Officer shall be an employee and a member of senior management of 21st Century, shall report directly to

 

2

 

the Chief Executive Officer of 21st Century, and shall not be or be subordinate to the General Counsel or Chief Financial Officer or have any responsibilities that involve acting in any capacity as legal counsel or supervising legal counsel functions for 21st Century. The Chief Compliance Officer shall be responsible for, without limitation:

 

a.                                      Maintaining, developing and implementing policies, procedures, and practices designed to ensure compliance with the requirements set forth in this CIA and with Federal health care program requirements;

 

b.                                      making periodic (at least quarterly) reports regarding compliance matters directly to the Board of Directors of 21st Century, and shall be authorized to report on such matters to the Board of Directors at any time. Written documentation of the Chief Compliance Officer’s reports to the Board of Directors shall be made available to OIG upon request; and

 

c.                                       monitoring the day-to-day compliance activities engaged in by 21st Century as well as for any reporting obligations created under this CIA.

 

Any noncompliance job responsibilities of the Chief Compliance Officer shall be limited and must not interfere with the Chief Compliance Officer’s ability to perform the duties outlined in this CIA.

 

21st Century shall report to OIG, in writing, any changes in the identity or position description of the Chief Compliance Officer, or any actions or changes that would affect the Chief Compliance Officer’s ability to perform the duties necessary to meet the obligations in this CIA, within five days after such a change.

 

2.                                      Regional Compliance Officers. 21st Century has appointed Regional Compliance Officers for each region (as defined by 21st Century) and shall maintain Regional Compliance Officers for the term of the CIA. The Regional Compliance Officers shall be responsible for maintaining and implementing policies, procedures, and practices designed to ensure compliance with the requirements set forth in this CIA and with Federal health care program requirements for the applicable regions, and shall monitor the day-to-day compliance activities for the applicable regions. The Regional Compliance Officers shall report to the Chief Compliance Officer and shall be members of the Compliance Committee. The Regional Compliance

 

3

 

Officers shall make periodic (at least quarterly) written reports regarding compliance matters directly to the Chief Compliance Officer, and shall be authorized to report on such matters directly to the Compliance Committee, the Chief Compliance Officer, and the Board of Directors at any time. The Regional Compliance Officers shall make periodic (at least monthly) visits to 21st Century practices in order to fulfill the obligation of this Section.

 

21st Century shall report to OIG, in writing, any changes in the identity or position description of the Regional Compliance Officers, or any actions or changes that would affect the Regional Compliance Officers’ ability to perform the duties necessary to meet the obligations in this CIA, within five days after such a change.

 

3.                                      Compliance Committee. 21st Century has an existing Compliance Committee. 21st Century shall maintain the Compliance Committee for the term of the CIA. The Compliance Committee shall, at a minimum, include the Chief Compliance Officer and other members of senior management necessary to meet the requirements of this CIA (e.g., senior executives of relevant departments, such as billing, clinical, human resources, audit, and operations). The Chief Compliance Officer shall continue to chair the Compliance Committee and the Committee shall support the Chief Compliance Officer in fulfilling his/her responsibilities (e.g., shall assist in the analysis of 21st Century’s risk areas and shall oversee monitoring of internal and external audits and investigations). The Compliance Committee shall meet at least quarterly. The minutes of the Compliance Committee meetings shall be made available to OIG upon request.

 

21st Century shall report to OIG, in writing, any changes in the composition of the Compliance Committee, or any actions or changes that would affect the Compliance Committee’s ability to perform the duties necessary to meet the obligations in this CIA, within 15 days after such a change.

 

4.                                      Board of Directors Compliance Obligations. The Board of Directors (or a committee of the Board) of 21st Century (Board) shall be responsible for the review and oversight of matters related to compliance with Federal health care program requirements and the obligations of this CIA. The Board must include independent (i.e., non-executive) members.

 

The Board shall, at a minimum, be responsible for the following:

 

4

 

a.                                      meeting at least quarterly to review and oversee 21st Century’s compliance program, including but not limited to the performance of the Chief Compliance Officer and Compliance Committee;

 

b.                                      submitting to the OIG a description of the documents and other materials it reviewed, as well as any additional steps taken, such as the engagement of an independent advisor or other third party resources, in its oversight of the compliance program and in support of making the resolution below during each Reporting Period; and

 

c.                                       for each Reporting Period of the CIA, adopting a resolution, signed by each member of the Board summarizing its review and oversight of 21st Century’s compliance with Federal health care program requirements and the obligations of this CIA.

 

d.                                      for the first Reporting Period of the CIA, the Board shall continue to retain an individual or entity with expertise in compliance with Federal health care program requirements (Compliance Expert) to perform a review of the effectiveness of 21st Century’s Compliance Program (Compliance Program Review). The Compliance Expert shall create a work plan for the Compliance Program Review and prepare a written report about the Compliance Program Review. The written report (Compliance Program Review Report) shall include a description of the Compliance Program Review and any recommendations with respect to 21st Century’s compliance program. During the first Reporting Period, the Board shall review the Compliance Program Review Report as part of its review and oversight of 21st Century’s compliance program. A copy of the Compliance Program Review report shall be provided to OIG in the first Annual Report submitted by 21st Century. In addition, copies of any materials provided to the Board by the Compliance Expert, along with minutes of any meetings between the Compliance Expert and the Board, shall be made available to the OIG upon request.

 

5

 

At minimum, the resolution shall include the following language:

 

“The Board of Directors has made a reasonable inquiry into the operations of 21st Century’s Compliance Program including the performance of the Chief Compliance Officer and the Compliance Committee. Based on its inquiry and review, the Board has concluded that, to the best of its knowledge, 21st Century has implemented and maintained an effective Compliance Program to meet Federal health care program requirements and the obligations of the CIA.”

 

If the Board is unable to provide such a conclusion in the resolution, the Board shall include in the resolution a written explanation of the reasons why it is unable to provide the conclusion and the steps it is taking to implement an effective Compliance Program at 21st Century.

 

21st Century shall report to OIG, in writing, any changes in the composition of the Board, or any actions or changes that would affect the Board’s ability to perform the duties necessary to meet the obligations in this CIA, within 15 days after such a change.

 

5.                                      Management Certifications. In addition to the responsibilities set forth in this CIA for all Covered Persons, certain 21st Century employees (Certifying Employees, are specifically expected to monitor and oversee activities within their areas of authority and shall annually certify that the applicable 21st department is in compliance with applicable Federal health care program requirements and with the obligations of this CIA. These Certifying Employees shall include, at a minimum, the following: Chief Executive Officer, Chief Medical Officer, Regional Compliance Officers, and Senior Vice Presidents for Operations. For each Reporting Period, each Certifying Employee shall sign a certification that states:

 

“I have been trained on and understand the compliance requirements and responsibilities as they relate to [insert name of department], an area under my supervision. My job responsibilities include ensuring compliance with regard to the [insert name of department] with all applicable Federal health care program requirements, obligations of the Corporate Integrity Agreement, and 21st Century policies, and I have taken steps to promote such compliance. To the best of my knowledge, the [insert name of department] of 21st Century is in compliance with all applicable Federal health care program requirements and the obligations of the Corporate

 

6

 

Integrity Agreement. I understand that this certification is being provided to and relied upon by the United States.”

 

If any Certifying Employee is unable to provide such a certification, the Certifying Employee shall provide a written explanation of the reasons why he or she is unable to provide the certification outlined above.

 

Within 90 days after the Effective Date, 21st Century shall develop and implement a written process for Certifying Employees to follow for the purpose of completing the certification required by this section (e.g., reports that must be reviewed, assessments that must be completed, sub-certifications that must be obtained, etc. prior to the Certifying Employee making the required certification).

 

B.                                    Written Standards

 

1.                                      Code of Conduct. 21st Century has developed, implemented, and distributed a written Code of Conduct to all Covered Persons, and shall maintain this Code of Conduct for the duration of the CIA. To the extent not already accomplished, within 90 days after the Effective Date, 21st Century shall make the performance of job responsibilities in a manner consistent with the Code of Conduct an element in evaluating the performance of all employees. The Code of Conduct shall, at a minimum, set forth:

 

a.                                      21st Century’s commitment to full compliance with all Federal health care program requirements, including its commitment to prepare and submit accurate claims consistent with such requirements;

 

b.                                      21st Century’s requirement that all of its Covered Persons shall be expected to comply with all Federal health care program requirements and with 21st Century’s policies and procedures;

 

c.                                       the requirement that all of 21st Century’s Covered Persons shall be expected to report to the Chief Compliance Officer, or other appropriate individual designated by 21st Century, suspected violations of any Federal health care program requirements or of 21st Century’s own Policies and Procedures; and

 

7

 

d.                                      the right of all individuals to use the Disclosure Program described in Section III.E, and 21st Century’s commitment to non-retaliation and to maintain, as appropriate, confidentiality and anonymity with respect to such disclosures.

 

21st Century shall continue to review the Code of Conduct at least annually to determine if revisions are appropriate and shall make any necessary revisions based on such review. The Code of Conduct shall be distributed at least annually to all Covered Persons.

 

2.                                      Policies and Procedures. 21st Century has developed, implemented, and distributed written policies and procedures regarding the operation of its compliance program, including the compliance program requirements outlined in this CIA and 21st Century’s compliance with Federal health care program requirements (Policies and Procedures). 21st Century shall maintain these Policies and Procedures for the duration of the CIA, which shall address, at a minimum:

 

a.                                      ensuring proper and accurate submission of all claims to Federal health care programs; and

 

b.                                      the Federal health care program billing, coding and claims submission statutes, regulations, program requirements, and directives relating to medical necessity determinations.

 

Throughout the term of this CIA, 21st Century shall enforce and comply with its Policies and Procedures and shall make such compliance an element of evaluating the performance of all employees.

 

Within 90 days after the Effective Date, 21st Century will ensure that the Policies and Procedures continue to be made available to all Covered Persons. Appropriate and knowledgeable staff shall be available to explain the Policies and Procedures.

 

21st Century shall continue, at least annually (and more frequently, if appropriate), assessing and updating, as necessary, the Policies and Procedures. Within 30 days after the effective date of any revisions or addition of new Policies and Procedures, a description of the revisions shall be communicated to all affected Covered Persons and any revised or new Policies and Procedures shall be made available to all Covered Persons.

 

8

 

C.                                    Training and Education

 

1.                                      Training Plan. Within 90 days after the Effective Date, 21st Century shall develop a written plan (Training Plan) that outlines the steps 21st Century will take to ensure that: (a) all Covered Persons receive adequate training regarding 21st Century’s CIA requirements and Compliance Program, including the Code of Conduct and (b) all Relevant Covered Persons receive adequate training regarding: (i) the Federal health care program requirements regarding the accurate coding and submission of claims; (ii) policies, procedures, and other requirements applicable to the documentation of medical records; (iii) the personal obligation of each individual involved in the claims submission process to ensure that such claims are accurate; (iv) applicable reimbursement statutes, regulations, and program requirements and directives; (v) the legal sanctions for violations of the Federal health care program requirements; and (vi) examples of proper and improper claims submission practices.

 

The Training Plan shall include information regarding the training topics, the categories of Covered Persons and Relevant Covered Persons required to attend each training session, the length of the training, the schedule for training, and the format of the training. Within 30 days of the OIG’s receipt of 21st Century’s Training Plan, OIG will notify 21st Century of any comments or objections to the Training Plan. Absent notification by the OIG that the Training Plan is unacceptable, 21st Century may implement its Training Plan. 21st Century shall furnish training to its Covered Persons and Relevant Covered Persons pursuant to the Training Plan during each Reporting Period.

 

2.                                      Board Member Training. Within 90 days after the Effective Date, 21st Century shall provide at least two hours of training to each member of the Board of Directors. This training shall address the 21st Century’s CIA requirements and Compliance Program (including the Code of Conduct), the corporate governance responsibilities of board members, and the responsibilities of board members with respect to review and oversight of the Compliance Program. Specifically, the training shall address the unique responsibilities of health care Board members, including the risks, oversight areas, and strategic approaches to conducting oversight of a health care entity. This training may be conducted by an outside compliance expert hired by the Board and should include a discussion of the OIG’s guidance on Board member responsibilities.

 

New members of the Board of Directors shall receive the Board Member Training described above within 30 days after becoming a member or within 90 days after the Effective Date, whichever is later.

 

9

 

3.                                      Certification. Each individual who is required to attend training shall certify, in writing or in electronic form, that he or she has received the required training. The certification shall specify the type of training received and the date received. The Chief Compliance Officer (or designee) shall retain the certifications, along with all course materials.

 

4.                                      Qualifications of Trainer. Persons providing the training shall be knowledgeable about the subject area.

 

5.                                      Update of Training Plan. 21st Century shall review the Training Plan annually, and, where appropriate, update the Training Plan to reflect changes in Federal health care program requirements, any issues discovered during internal audits or the Claims Review, and any other relevant information. Any updates to the Training Plan must be reviewed and approved by the OIG prior to the implementation of the revised Training Plan. Within 30 days of OIG’s receipt of any updates or revisions to 21st Century’s Training Plan, OIG will notify 21st Century of any comments or objections to the revised Training Plan. Absent notification from the OIG that the revised Training Plan is unacceptable, 21st Century may implement the revised Training Plan.

 

6.                                      Computer-based Training. 21st Century may provide the training required under this CIA through appropriate computer-based training approaches. If 21st Century chooses to provide computer-based training, it shall make available appropriately qualified and knowledgeable staff or trainers to answer questions or provide additional information to the individuals receiving such training.

 

D.                                    Review Procedures

 

1.                                      General Description

 

a.                                      Engagement of Independent Review Organization. Within 90 days after the Effective Date, 21st Century shall engage an entity (or entities), such as an accounting, auditing, or consulting firm (hereinafter “Independent Review Organization” or “IRO”), to perform the reviews listed in this Section III.D. The applicable requirements relating to the IRO are outlined in Appendix A to this CIA, which is incorporated by reference.

 

10

 

b.                                      Retention of Records. The IRO and 21st Century shall retain and make available to OIG, upon request, all work papers, supporting documentation, correspondence, and draft reports (those exchanged between the IRO and 21st Century) related to the reviews.

 

2.                                              Claims Review. The IRO shall review 21st Century’s claims to the Medicare and TRICARE programs and the reimbursement received (Claims Review), pursuant to the applicable coverage, billing, coding, and medical necessity requirements, regulations, and/or guidance to determine whether the items and services provided were medically necessary, and the claims were correctly coded, submitted, and reimbursed. The IRO shall prepare a Claims Review Report, as outlined in Appendix B to this CIA, which is incorporated by reference.

 

3.                                              Validation Review. In the event OIG has reason to believe that: (a) any Claims Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review complied with the requirements of the CIA and/or the findings or Claims Review results are inaccurate (Validation Review). 21st Century shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of a Claims Review submitted as part of 21st Century’s final Annual Report shall be initiated no later than one year after 21st Century’s final submission (as described in Section II) is received by OIG.

 

Prior to initiating a Validation Review, OIG shall notify 21st Century in writing of its intent to do so and provide an explanation of the reasons OIG has determined a Validation Review is necessary. 21st Century shall have 30 days following the date of the OIG’s written notice to submit a written response to OIG that includes any additional or relevant information to clarify the results of the Claims Review or to correct the inaccuracy of the Claims Review and/or propose alternatives to the proposed Validation Review. The final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

 

4.                                              Independence and Objectivity Certification. The IRO shall include in its report(s) to 21st Century a certification that the IRO has (a) evaluated its professional independence and objectivity with respect to the reviews required under this Section III.D and (b) concluded that it is, in fact, independent and objective, in accordance with the requirements specified in Appendix A to this CIA.

 

11

 

E.                                     Risk Assessment and Internal Review Process

 

21st Century has developed and implemented a risk assessment and internal review process to identify and address risks associated with the submission of claims for items and services furnished to Medicare and TRICARE program beneficiaries, and will continue to maintain this risk assessment and internal review process during the term of the CIA. The risk assessment and internal review process shall require compliance, legal, and department leaders, at least annually, to: (1) identify and prioritize risks, (2) develop internal audit work plans related to the identified risk areas, (3) implement the internal audit work plans, (4) develop corrective action plans in response to the results of any internal audits performed, and (5) track the implementation of the corrective action plans in order to assess the effectiveness of such plans. 21st Century shall maintain the risk assessment and internal review process for the term of the CIA.

 

F.                                      Disclosure Program

 

21st Century has established a Disclosure Program, and will continue to maintain a Disclosure Program, that includes a mechanism (e.g., a toll-free compliance telephone line) to enable individuals to disclose, to the Chief Compliance Officer or some other person who is not in the disclosing individual’s chain of command, any identified issues or questions associated with 21st Century’s policies, conduct, practices, or procedures with respect to a Federal health care program believed by the individual to be a potential violation of criminal, civil, or administrative law. 21st Century shall appropriately publicize the existence of the disclosure mechanism (e.g., via periodic e-mails to employees or by posting the information in prominent common areas).

 

The Disclosure Program shall emphasize a non-retribution, non-retaliation policy, and shall include a reporting mechanism for anonymous communications for which appropriate confidentiality shall be maintained. Upon receipt of a disclosure, the Chief Compliance Officer (or designee) shall continue to gather all relevant information from the disclosing individual. The Chief Compliance Officer (or designee) shall continue to make a preliminary, good faith inquiry into the allegations set forth in every disclosure to ensure that he or she has obtained all of the information necessary to determine whether a further review should be conducted. For any disclosure that is sufficiently specific so that it reasonably: (1) permits a determination of the appropriateness of the alleged improper practice; and (2) provides an opportunity for taking corrective action, 21st Century shall continue to conduct an internal review of the allegations set forth in the disclosure and ensure that proper follow-up is conducted.

 

12

 

The Chief Compliance Officer (or designee) shall continue to maintain a disclosure log and shall record each disclosure in the disclosure log within two business days of receipt of the disclosure. The disclosure log shall continue to include a summary of each disclosure received (whether anonymous or not), the status of the respective internal reviews, and any corrective action taken in response to the internal reviews.

 

G.                                    Ineligible Persons

 

1.                                      Definitions. For purposes of this CIA:

 

a.                                      an “Ineligible Person” shall include an individual or entity who:

 

i.                                          is currently excluded, debarred, or suspended from participation in the Federal health care programs or in Federal procurement or non-procurement programs; or

 

ii.                                       has been convicted of a criminal offense that falls within the scope of 42 U.S.C. § 1320a-7(a), but has not yet been excluded, debarred, or suspended.

 

b.                                      “Exclusion Lists” include:

 

i.              the HHS/OIG List of Excluded Individuals/Entities (LEIE) (available through the Internet at http://www.oig.hhs.gov); and

 

ii.             the General Services Administration’s System for Award Management (SAM) (available through the Internet at http://www.sam.gov).

 

2.                                      Screening Requirements. To the extent not already accomplished, within 90 days, 21st Century shall ensure that all prospective and current Covered Persons are not Ineligible Persons, by implementing the following screening requirements.

 

a.                                      21st Century shall screen all prospective Covered Persons against the Exclusion Lists prior to engaging their services

 

13

 

and, as part of the hiring or contracting process, shall require such Covered Persons to disclose whether they are Ineligible Persons.

 

b.                                      21st Century shall screen all current Covered Persons against the Exclusion Lists within 90 days after the Effective Date and thereafter shall screen against the LEIE on a monthly basis and screen against SAM on an annual basis.

 

c.                                       21st Century shall implement a policy requiring all Covered Persons to disclose immediately any debarment, exclusion, or suspension.

 

Nothing in this Section III.G affects 21st Century’s responsibility to refrain from (and liability for) billing Federal health care programs for items or services furnished, ordered, or prescribed by an excluded person. 21st Century understands that items or services furnished, ordered, or prescribed by excluded persons are not payable by Federal health care programs and that 21st Century may be liable for overpayments and/or criminal, civil, and administrative sanctions for employing or contracting with an excluded person regardless of whether 21st Century meets the requirements of Section III.G.

 

3.                                      Removal Requirement. If 21st Century has actual notice that a Covered Person has become an Ineligible Person, 21st Century shall remove such Covered Person from responsibility for, or involvement with, 21st Century’s business operations related to the Federal health care programs and shall remove such Covered Person from any position for which the Covered Person’s compensation or the items or services furnished, ordered, or prescribed by the Covered Person are paid in whole or part, directly or indirectly, by Federal health care programs or otherwise with Federal funds at least until such time as the Covered Person is reinstated into participation in the Federal health care programs.

 

4.                                      Pending Charges and Proposed Exclusions. If 21st Century has actual notice that a Covered Person is charged with a criminal offense that falls within the scope of 42 U.S.C. §§ 1320a-7(a), 1320a-7(b)(1)-(3), or is proposed for exclusion during the Covered Person’s employment or contract term, 21st Century shall take all appropriate actions to ensure that the responsibilities of that Covered Person have not and shall not adversely affect the quality of care rendered to any beneficiary or the accuracy of any claims submitted to any Federal health care program.

 

14

 

H.                                   Notification of Government Investigation or Legal Proceeding

 

Within 30 days after discovery, 21st Century shall notify OIG, in writing, of any ongoing investigation or legal proceeding known to 21st Century conducted or brought by a governmental entity or its agents involving an allegation that 21st Century has committed a crime or has engaged in fraudulent activities. This notification shall include a description of the allegation, the identity of the investigating or prosecuting agency, and the status of such investigation or legal proceeding. 21st Century shall also provide written notice to OIG within 30 days after the resolution of the matter, and shall provide OIG with a description of the findings and/or results of the investigation or proceeding, if any.

 

I.                                        Overpayments

 

1.                                      Definition of Overpayments. For purposes of this CIA, an “Overpayment” shall mean the amount of money 21st Century has received in excess of the amount due and payable under any Federal health care program requirements.

 

2.                                      Overpayment Policies and Procedures. To the extent not already accomplished, within 90 days after the Effective Date, 21st Century shall develop and implement written policies and procedures regarding the identification, quantification and repayment of Overpayments received from any Federal health care program.

 

3.                                      Repayment of Overpayments.

 

a.                                      If, at any time, 21st Century identifies any Overpayment, 21st Century shall repay the Overpayment to the appropriate payor (e.g., Medicare contractor) within 60 days after identification of the Overpayment and take remedial steps within 90 days after identification (or such additional time as may be agreed to by the payor) to correct the problem, including preventing the underlying problem and the Overpayment from recurring. If not yet quantified within 60 days after identification, 21st Century shall notify the payor of its efforts to quantify the Overpayment amount along with a schedule of when such work is expected to be completed. Notification and repayment to the payor shall be done in accordance with the payor’s policies.

 

15

 

b.                                      Notwithstanding the above, notification and repayment of any Overpayment amount that routinely is reconciled or adjusted pursuant to policies and procedures established by the payor should be handled in accordance with such policies and procedures.

 

J.                                        Reportable Events

 

1.                                      Definition of Reportable Event. For purposes of this CIA, a “Reportable Event” means anything that involves:

 

a.                                      a substantial Overpayment;

 

b.                                      a matter that a reasonable person would consider a probable violation of criminal, civil, or administrative laws applicable to any Federal health care program for which penalties or exclusion may be authorized;

 

c.                                       the employment of or contracting with a Covered Person who is an Ineligible Person as defined by Section III.G.1.a; or

 

d.                                      the filing of a bankruptcy petition by 21st Century.

 

A Reportable Event may be the result of an isolated event or a series of occurrences.

 

2.                                      Reporting of Reportable Events. If 21st Century determines (after a reasonable opportunity to conduct an appropriate review or investigation of the allegations) through any means that there is a Reportable Event, 21st Century shall notify OIG, in writing, within 30 days after making the determination that the Reportable Event exists.

 

3.                                      Reportable Events under Section III.J.1.a. For Reportable Events under Section III.J.1.a, the report to OIG shall be made within 30 days after making a determination that a substantial Overpayment exists and shall include:

 

a.                                      a complete description of all details relevant to the Reportable Event, including, at a minimum, the types of claims, transactions or other conduct giving rise to the Reportable

 

16

 

Event; the period during which the conduct occurred; and the names of entities and individuals believed to be implicated, including an explanation of their roles in the Reportable Event;

 

b.                                      the Federal health care programs affected by the Reportable Event;

 

c.                                       a description of the steps taken by 21st Century to identity and quantify the Overpayment; and

 

d.                                      a description of 21st Century’s actions taken to correct the Reportable Event and prevent it from recurring.

 

Within 60 days of identification of the Overpayment, 21st Century shall provide OIG with a copy of the notification and repayment (if quantified) to the payor required in Section III.I.3.

 

4.                                      Reportable Events under Section III.J.1.b. For Reportable Events under Section III.J.1.b, the report to OIG shall include:

 

a.                                      a complete description of all details relevant to the Reportable Event, including, at a minimum, the types of claims, transactions or other conduct giving rise to the Reportable Event; the period during which the conduct occurred; and the names of entities and individuals believed to be implicated, including an explanation of their roles in the Reportable Event;

 

b.                                      a statement of the Federal criminal, civil or administrative laws that are probably violated by the Reportable Event;

 

c.                                       the Federal health care programs affected by the Reportable Event;

 

d.                                      a description of 21st Century’s actions taken to correct the Reportable Event and prevent it from recurring; and

 

17

 

e.                                       if the Reportable Event has resulted in an Overpayment, a description of the steps taken by 21st Century to identify and quantify the Overpayment.

 

5.                                      Reportable Events under Section III.J.1.c. For Reportable Events under Section III.J.1.c, the report to OIG shall include:

 

a.                                      the identity of the Ineligible Person and the job duties performed by that individual;

 

b.                                      the dates of the Ineligible Persons employment or contractual relationship;

 

c.                                       a description of the Exclusion Lists screening that 21st Century completed before and/or during the Ineligible Person’s employment or contract and any flaw or breakdown in the Ineligible Persons screening process that led to the hiring or contracting with the Ineligible Person;

 

d.                                      a description of how the Reportable Event was discovered; and

 

e.                                       a description of any corrective action implemented to prevent future employment or contracting with an Ineligible Person.

 

6.                                      Reportable Events under Section III.J.1.d. For Reportable Events under Section III.J.1.d, the report to the OIG shall include documentation of the bankruptcy filing and a description of any Federal health care program authorities implicated.

 

7.                                      Reportable Events Involving the Stark Law. Notwithstanding the reporting requirements outlined above, any Reportable Event that involves solely a probable violation of section 1877 of the Social Security Act, 42 U.S.C. §1395nn (the Stark Law) should be submitted by 21st Century to the Centers for Medicare & Medicaid Services (CMS) through the self-referral disclosure protocol (SRDP), with a copy to the OIG. The requirements of Section III.I.3 that require repayment to the payor of any identified Overpayment within 60 days shall not apply to any Overpayment that may result from a probable violation of solely the Stark Law that is disclosed to CMS pursuant to the SRDP. If 21st Century identifies a probable violation of the Stark Law and repays

 

18

 

the applicable Overpayment directly to the CMS contractor, then 21st Century is not required by this Section III.J to submit the Reportable Event to CMS through the SRDP.

 

IV.                               SUCCESSOR LIABILITY; CHANGES TO BUSINESS UNITS OR LOCATIONS

 

A.                                    Sale of Business, Business Unit or Location

 

In the event that, after the Effective Date, 21st Century proposes to sell any or all of its business, business units or locations (whether through a sale of assets, sale of stock, or other type of transaction) that are subject to this CIA, 21st Century shall notify OIG of the proposed sale at least 30 days prior to the sale of its business, business unit or location. This notification shall include a description of the business, business unit or location to be sold, a brief description of the terms of the sale, and the name and contact information of the prospective purchaser. This CIA shall be binding on the purchaser of the business, business unit or location, unless otherwise determined and agreed to in writing by the OIG.

 

B.                                    Change or Closure of Business, Business Unit or Location

 

In the event that, after the Effective Date, 21st Century changes locations or closes a business, business unit or location related to the furnishing of items or services that may be reimbursed by Federal health care programs, 21st Century shall notify OIG of this fact as soon as possible, but no later than 30 days after the date of change or closure of the business, business unit or location.

 

C.                                    Purchase or Establishment of New Business, Business Unit or Location

 

In the event that, after the Effective Date, 21st Century purchases or establishes a new business, business unit or location related to the furnishing of items or services that may be reimbursed by Federal health care programs, 21st Century shall notify OIG at least 30 days prior to such purchase or the operation of the new business, business unit or location. This notification shall include the address of the new business, business unit or location, phone number, fax number, the location’s Medicare and TRICARE program provider number and/or supplier number(s) and the name and address of each Medicare and TRICARE program contractor to which 21st Century currently submits claims. Each such new business, business unit or location and all Covered Persons at each new

 

19

 

business, business unit or location shall be subject to the applicable requirements of this CIA, unless otherwise determined and agreed to in writing by the OIG.

 

V.                                    IMPLEMENTATION AND ANNUAL REPORTS

 

A.                                    Implementation Report

 

Within 120 days after the Effective Date, 21st Century shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:

 

1.                                      the name, address, phone number, and position description of the Chief Compliance Officer required by Section III.A.1, and a summary of other noncompliance job responsibilities the Chief Compliance Officer may have;

 

2.                                      the names, addresses, phone numbers, and position descriptions of the Regional Compliance Officers required by Section III.A.2,

 

3.                                      the names and positions of the members of the Compliance Committee required by Section III.A.3;

 

4.                                      the names of the Board members who are responsible for satisfying the Board of Directors compliance obligations described in Section III.A.4;

 

5.                                      the names and positions of the Certifying Employees required by Section III.A.5.

 

6.                                      a copy of 21st Century’s Code of Conduct required by Section III.B.1;

 

7.                                      a summary of all Policies and Procedures required by Section III.B (copies of the Policies and Procedures shall be made available to OIG upon request);

 

8.                                      the Training Plan required by Section III.C.1 and a description of the Board of Directors training required by Section III.C.2 (including a summary of the topics covered, the length of the training; and when the training was provided);

 

20

 

9.                                      the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; (d) a summary and description of any and all current and prior engagements and agreements between 21st Century and the IRO; and (e) a certification from the IRO regarding its professional independence and objectivity with respect to 21st Century;

 

10.                               a description of the risk assessment and internal review process required by Section III.E;

 

11.                               a description of the Disclosure Program required by Section III.F;

 

12.                               a certification that 21st Century has implemented screening requirements described in Section III.G regarding Ineligible Persons, or a description of why 21st Century cannot provide such a certification;

 

13.                               a copy of 21st Century’s policies and procedures regarding the identification, quantification and repayment of Overpayments required by Section III.I;

 

14.                               a list of all of 21st Century’s locations (including locations and mailing addresses); the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers, each location’s Medicare and TRICARE program provider number(s) and/or supplier number(s), and the name and address of each Medicare and TRICARE program contractor to which 21st Century currently submits claims;

 

15.                               a description of 21st Century’s corporate structure, including identification of any parent and sister companies, subsidiaries, and their respective lines of business; and

 

16.                               the certifications required by Section V.C.

 

B.                                    Annual Reports

 

21st Century shall submit to OIG annually a report with respect to the status of, and findings regarding, 21st Century’s compliance activities for each of the five Reporting Periods (Annual Report). Each Annual Report shall include, at a minimum:

 

21

 

1.                                      any change in the identity, position description, or other noncompliance job responsibilities of the Chief Compliance Officer described in Section III.A.1; any change in the identity, or position description of the Regional Compliance Officers described in Section III.A.2; any change in the membership of the Compliance Committee described in Section III.A.3; any change in the Board members who are responsible for satisfying the Board of Directors compliance obligations described in Section III.A.4; and any change in the group of Certifying Employees described in Section III.A.5.

 

2.                                      the dates of each report made by the Chief Compliance Officer to the Board (written documentation of such reports shall be made available to OIG upon request);

 

3.                                      the Board resolution required by Section III.A.4 and a description of the documents and other materials reviewed by the Board, as well as any additional steps taken, in its oversight of the compliance program and in support of making the resolution;

 

4.                                      a copy of the Compliance Program Review Report as required by Section III.A.4.d;

 

5.                                      a summary of any significant changes or amendments to 21st Century’s Code of Conduct or the Policies and Procedures required by Section III.B and the reasons for such changes (e.g., change in contractor policy);

 

6.                                      a copy of 21st Century’s Training Plan developed under Section III.C and the following information regarding each type of training required by the Training Plan: a description of the training, including a summary of the topics covered; the length of sessions, a schedule of training sessions, a general description of the categories of individuals required to complete the training, and the process by which 21st Century ensures that all designated employees receive appropriate training. A copy of all training materials and the documentation to support this information shall be made available to OIG upon request.

 

7.                                      a complete copy of all reports prepared pursuant to Section III.D, along with a copy of the IRO’s engagement letter, and 21st Century’s response to the reports, along with corrective action plan(s) related to any issues raised by the reports;

 

8.                                      a summary and description of any and all current and prior engagements and agreements between 21st Century and the IRO (if different from what

 

22

 

was submitted as part of the Implementation Report) and a certification from the IRO regarding its professional independence and objectivity with respect to 21st Century;

 

9.                                      a description of the risk assessment and internal review process required by Section III.E, a summary of any changes to the process, and a description of the reasons for such changes;

 

10.                               a summary of all internal audits performed pursuant to Section III.E during the Reporting Period and any corrective action plans developed in response to those internal audits. Copies of the internal audit reports and corrective action plans shall be made available to OIG upon request;

 

11.                               a summary of the disclosures in the disclosure log required by Section III.F that relate to Federal health care programs (the complete disclosure log shall be made available to OIG upon request);

 

12.                               a certification that 21st Century has completed the screening required by Section III.G regarding Ineligible Persons;

 

13.                               a summary describing any ongoing investigation or legal proceeding required to have been reported pursuant to Section III.H. The summary shall include a description of the allegation, the identity of the investigating or prosecuting agency, and the status of such investigation or legal proceeding;

 

14.                               a description of any changes to the Overpayment policies and procedures required by Section III.I, including the reasons for such changes;

 

15.                               a report of the aggregate Overpayments that have been returned to the Federal health care programs. Overpayment amounts shall be broken down into the following categories: Medicare and TRICARE (report each applicable state separately, if applicable), and other Federal health care programs. Overpayment amounts that are routinely reconciled or adjusted pursuant to policies and procedures established by the payor do not need to be included in this aggregate Overpayment report;

 

16.                               a summary of Reportable Events (as defined in Section III.J) identified during the Reporting Period and the status of any corrective action relating to all such Reportable Events;

 

23

 

17.                               a summary describing any audits conducted during the applicable Reporting Period by a Medicare or TRICARE program contractor or any government entity or contractor, involving a review of Federal health care program claims, and 21st Century’s response/corrective action plan (including information regarding any Federal health care program refunds) relating to the audit findings;

 

18.                               a description of all changes to the most recently provided list of 21st Century’s locations (including addresses) as required by Section V.A.13; and

 

19.                               the certifications required by Section V.C.

 

The first Annual Report shall be received by OIG no later than 60 days after the end of the first Reporting Period. Subsequent Annual Reports shall be received by OIG no later than the anniversary date of the due date of the first Annual Report.

 

C.                                    Certifications

 

1.                                      Certifying Employees. In each Annual Report, 21st Century shall include the certifications of Certifying Employees as required by Section III.A.5.

 

2.                                      Chief Compliance Officer and Chief Executive Officer. The Implementation Report and each Annual Report shall include a certification by the Chief Compliance Officer and Chief Executive Officer that:

 

a.                                      to the best of his or her knowledge, except as otherwise described in the report, 21st Century is in compliance with all of the requirements of this CIA; and

 

b.                                      he or she has reviewed the report and has made reasonable inquiry regarding its content and believes that the information in the report is accurate and truthful.

 

3.                                      Chief Financial Officer. The first Annual Report shall include a certification by the Chief Financial Officer that, to the best of his or her knowledge, 21st Century has complied with its obligations under the Settlement Agreement: (a) not to resubmit to any Federal health care program payors any previously denied claims related to the Covered Conduct addressed in the Settlement Agreement, and not to appeal any such denials of claims; (b) not to charge to or otherwise seek payment from federal or

 

24

 

state payors for unallowable costs (as defined in the Settlement Agreement); and (c) to identify and adjust any past charges or claims for unallowable costs.

 

D.                                    Designation of Information

 

21st Century shall clearly identify any portions of its submissions that it believes are trade secrets, or information that is commercial or financial and privileged or confidential, and therefore potentially exempt from disclosure under the Freedom of Information Act (FOIA), 5 U.S.C. § 552. 21st Century shall refrain from identifying any information as exempt from disclosure if that information does not meet the criteria for exemption from disclosure under FOIA.

 

VI.                               NOTIFICATIONS AND SUBMISSION OF REPORTS

 

Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities:

 

OIG:

 

Administrative and Civil Remedies Branch

Office of Counsel to the Inspector General

Office of Inspector General

U.S. Department of Health and Human Services

Cohen Building, Room 5527

330 Independence Avenue, S.W.

Washington, DC 20201

Telephone: 202.619.2078

Facsimile: 202.205.0604

 

21st Century:

 

Compliance Officer

21st Century Oncology, LLC

2270 Colonial Boulevard

Fort Myers, FL 33907

Telephone:                    (239) 931-7333

Facsimile:                          (239) 931-7380

 

25

 

Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, 21st Century may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), in addition to a paper copy.

 

VII.                          OIG INSPECTION, AUDIT, AND REVIEW RIGHTS

 

In addition to any other rights OIG may have by statute, regulation, or contract, OIG or its duly authorized representative(s) may examine and/or request copies of 21st Century’s books, records, and other documents and supporting materials and/or conduct on-site reviews of any of 21st Century’s locations for the purpose of verifying and evaluating: (a) 21st Century’s compliance with the terms of this CIA and (b) 21st Century’s compliance with the requirements of the Federal health care programs. The documentation described above shall be made available by 21st Century to OIG or its duly authorized representative(s) at all reasonable times for inspection, audit, and/or reproduction. Furthermore, for purposes of this provision, OIG or its duly authorized representative(s) may interview any of 21st Century’s Covered Persons who consent to be interviewed at the individual’s place of business during normal business hours or at such other place and time as may be mutually agreed upon between the individual and OIG. 21st Century shall assist OIG or its duly authorized representative(s) in contacting and arranging interviews with such individuals upon OIG’s request. 21st Century’s Covered Persons may elect to be interviewed with or without a representative of 21st Century present.

 

VIII.                     DOCUMENT AND RECORD RETENTION

 

21st Century shall maintain for inspection all documents and records relating to reimbursement from the Federal health care programs and to compliance with this CIA for six years (or longer if otherwise required by law) from the Effective Date.

 

IX.                              DISCLOSURES

 

Consistent with HHS’s FOIA procedures, set forth in 45 C.F.R. Part 5, OIG shall make a reasonable effort to notify 21st Century prior to any release by OIG of information submitted by 21st Century pursuant to its obligations under this CIA and identified upon submission by 21st Century as trade secrets, or information that is

 

26

 

commercial or financial and privileged or confidential, under the FOIA rules. With respect to such releases, 21st Century shall have the rights set forth at 45 C.F.R. § 5.65(d).

 

X.                                   BREACH AND DEFAULT PROVISIONS

 

21st Century is expected to fully and timely comply with all of its CIA obligations.

 

A.                                    Stipulated Penalties for Failure to Comply with Certain Obligations

 

As a contractual remedy, 21st Century and OIG hereby agree that failure to comply with certain obligations as set forth in this CIA may lead to the imposition of the following monetary penalties (hereinafter referred to as “Stipulated Penalties”) in accordance with the following provisions.

 

1.                                      A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day 21st Century fails to establish and implement any of the following obligations as described in Sections III and IV:

 

a.                                      a Chief Compliance Officer;

 

b.                                      Regional Compliance Officers;

 

c.                                       a Compliance Committee;

 

d.                                      the Board of Directors compliance obligations and the engagement of a Compliance Expert, the performance of a Compliance Program Review and the preparation of a Compliance Program Review Report, as required by Section III.A.3.

 

e.                                       the management certification obligations;

 

f.                                        a written Code of Conduct;

 

g.                                       written Policies and Procedures;

 

27

 

h.                                      the development and/or implementation of a Training Plan for the training of Covered Persons, Relevant Covered Persons, and Board Members;

 

i.                                          a risk assessment and internal review process as required by Section III.E;

 

j.                                         a Disclosure Program;

 

k.                                      Ineligible Persons screening and removal requirements;

 

l.                                          notification of Government investigations or legal proceedings;

 

m.                                  policies and procedures regarding the repayment of Overpayments;

 

n.                                      the repayment of Overpayments as required by Section III.I and Appendix B;

 

o.                                      reporting of Reportable Events; and

 

p.                                      disclosure of changes to business units or locations.

 

2.                                      A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day 21st Century fails to engage and use an IRO, as required by Section III.D, Appendix A, or Appendix B.

 

3.                                      A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day 21st Century fails to submit the Implementation Report or any Annual Reports to OIG in accordance with the requirements of Section V by the deadlines for submission.

 

4.                                      A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day 21st Century fails to submit any Claims Review Report in accordance with the requirements of Section III.D and Appendix B.

 

28

 

5.                                      A Stipulated Penalty of $1,500 for each day 21st Century fails to grant access as required in Section VII. (This Stipulated Penalty shall begin to accrue on the date 21st Century fails to grant access.)

 

6.                                      A Stipulated Penalty of $50,000 for each false certification submitted by or on behalf of 21st Century as part of its Implementation Report, any Annual Report, additional documentation to a report (as requested by the OIG), or otherwise required by this CIA.

 

7.                                      A Stipulated Penalty of $1,000 for each day 21st Century fails to comply fully and adequately with any obligation of this CIA. OIG shall provide notice to 21st Century stating the specific grounds for its determination that 21st Century has failed to comply fully and adequately with the CIA obligation(s) at issue and steps 21st Century shall take to comply with the CIA. (This Stipulated Penalty shall begin to accrue 10 days after the date 21st Century receives this notice from OIG of the failure to comply.) A Stipulated Penalty as described in this Subsection shall not be demanded for any violation for which OIG has sought a Stipulated Penalty under Subsections 1- 6 of this Section.

 

B.                                    Timely Written Requests for Extensions

 

21st Century may, in advance of the due date, submit a timely written request for an extension of time to perform any act or file any notification or report required by this CIA. Notwithstanding any other provision in this Section, if OIG grants the timely written request with respect to an act, notification, or report, Stipulated Penalties for failure to perform the act or file the notification or report shall not begin to accrue until one day after 21st Century fails to meet the revised deadline set by OIG. Notwithstanding any other provision in this Section, if OIG denies such a timely written request, Stipulated Penalties for failure to perform the act or file the notification or report shall not begin to accrue until three days after 21st Century receives OIG’s written denial of such request or the original due date, whichever is later. A “timely written request” is defined as a request in writing received by OIG at least five days prior to the date by which any act is due to be performed or any notification or report is due to be filed.

 

C.                                    Payment of Stipulated Penalties

 

1.                                      Demand Letter. Upon a finding that 21st Century has failed to comply with any of the obligations described in Section X.A and after determining that Stipulated Penalties are appropriate, OIG shall notify 21st Century of: (a) 21st Century’s

 

29

 

failure to comply; and (b) OIG’s exercise of its contractual right to demand payment of the Stipulated Penalties. (This notification shall be referred to as the “Demand Letter.”)

 

2.                                      Response to Demand Letter. Within 10 days after the receipt of the Demand Letter, 21st Century shall either: (a) cure the breach to OIG’s satisfaction and pay the applicable Stipulated Penalties or (b) request a hearing before an HHS administrative law judge (ALJ) to dispute OIG’s determination of noncompliance, pursuant to the agreed upon provisions set forth below in Section X.E. In the event 21st Century elects to request an ALJ hearing, the Stipulated Penalties shall continue to accrue until 21st Century cures, to OIG’s satisfaction, the alleged breach in dispute. Failure to respond to the Demand Letter in one of these two manners within the allowed time period shall be considered a material breach of this CIA and shall be grounds for exclusion under Section X.D.

 

3.                                      Form of Payment. Payment of the Stipulated Penalties shall be made by electronic funds transfer to an account specified by OIG in the Demand Letter.

 

4.                                      Independence from Material Breach Determination. Except as set forth in Section X.D.1.c, these provisions for payment of Stipulated Penalties shall not affect or otherwise set a standard for OIG’s decision that 21st Century has materially breached this CIA, which decision shall be made at OIG’s discretion and shall be governed by the provisions in Section X.D, below.

 

D.                                    Exclusion for Material Breach of this CIA

 

1.                                      Definition of Material Breach. A material breach of this CIA means:

 

a.                                      repeated violations or a flagrant violation of any of the obligations under this CIA, including, but not limited to, the obligations addressed in Section X.A;

 

b.                                      a failure by 21st Century to report a Reportable Event, take corrective action, or make the appropriate refunds, as required in Section III.J;

 

c.                                       a failure to respond to a Demand Letter concerning the payment of Stipulated Penalties in accordance with Section X.C; or

 

30

 

d.                                      a failure to engage and use an IRO in accordance with Section III.D, Appendix A, or Appendix B.

 

2.                                      Notice of Material Breach and Intent to Exclude. The parties agree that a material breach of this CIA by 21st Century constitutes an independent basis for 21st Century’s exclusion from participation in the Federal health care programs. The length of the exclusion shall be in the OIG’s discretion, but not more than five years per material breach. Upon a determination by OIG that 21st Century has materially breached this CIA and that exclusion is the appropriate remedy, OIG shall notify 21st Century of: (a) 21st Century’s material breach; and (b) OIG’s intent to exercise its contractual right to impose exclusion. (This notification shall be referred to as the “Notice of Material Breach and Intent to Exclude.”)

 

3.                                      Opportunity to Cure. 21st Century shall have 30 days from the date of receipt of the Notice of Material Breach and Intent to Exclude to demonstrate that:

 

a.                                      the alleged material breach has been cured; or

 

b.                                      the alleged material breach cannot be cured within the 30 day period, but that: (i) 21st Century has begun to take action to cure the material breach; (ii) 21st Century is pursuing such action with due diligence; and (iii) 21st Century has provided to OIG a reasonable timetable for curing the material breach.

 

4.                                      Exclusion Letter. If, at the conclusion of the 30 day period, 21st Century fails to satisfy the requirements of Section X.D.3, OIG may exclude 21st Century from participation in the Federal health care programs. OIG shall notify 21st Century in writing of its determination to exclude 21st Century. (This letter shall be referred to as the “Exclusion Letter.”) Subject to the Dispute Resolution provisions in Section X.E, below, the exclusion shall go into effect 30 days after the date of 21st Century’s receipt of the Exclusion Letter. The exclusion shall have national effect. Reinstatement to program participation is not automatic. At the end of the period of exclusion, 21st Century may apply for reinstatement by submitting a written request for reinstatement in accordance with the provisions at 42 C.F.R. §§ 1001.3001-.3004.

 

31

 

E.                                     Dispute Resolution

 

1.                                      Review Rights. Upon OIG’s delivery to 21st Century of its Demand Letter or of its Exclusion Letter, and as an agreed-upon contractual remedy for the resolution of disputes arising under this CIA, 21st Century shall be afforded certain review rights comparable to the ones that are provided in 42 U.S.C. § 1320a-7(f) and 42 C.F.R. Part 1005 as if they applied to the Stipulated Penalties or exclusion sought pursuant to this CIA. Specifically, OIG’s determination to demand payment of Stipulated Penalties or to seek exclusion shall be subject to review by an HHS ALJ and, in the event of an appeal, the HHS Departmental Appeals Board (DAB), in a manner consistent with the provisions in 42 C.F.R. § 1005.2-1005.21. Notwithstanding the language in 42 C.F.R. § 1005.2(c), the request for a hearing involving Stipulated Penalties shall be made within 10 days after receipt of the Demand Letter and the request for a hearing involving exclusion shall be made within 25 days after receipt of the Exclusion Letter. The procedures relating to the filing of a request for a hearing can be found at http://www.hhs.gov/dab/divisions/civil/procedures/divisionprocedures.html.

 

2.                                      Stipulated Penalties Review. Notwithstanding any provision of Title 42 of the United States Code or Title 42 of the Code of Federal Regulations, the only issues in a proceeding for Stipulated Penalties under this CIA shall be: (a) whether 21st Century was in full and timely compliance with the obligations of this CIA for which OIG demands payment; and (b) the period of noncompliance. 21st Century shall have the burden of proving its full and timely compliance and the steps taken to cure the noncompliance, if any. OIG shall not have the right to appeal to the DAB an adverse ALJ decision related to Stipulated Penalties. If the ALJ agrees with OIG with regard to a finding of a breach of this CIA and orders 21st Century to pay Stipulated Penalties, such Stipulated Penalties shall become due and payable 20 days after the ALJ issues such a decision unless 21st Century requests review of the ALJ decision by the DAB. If the ALJ decision is properly appealed to the DAB and the DAB upholds the determination of OIG, the Stipulated Penalties shall become due and payable 20 days after the DAB issues its decision.

 

3.                                      Exclusion Review. Notwithstanding any provision of Title 42 of the United States Code or Title 42 of the Code of Federal Regulations, the only issues in a proceeding for exclusion based on a material breach of this CIA shall be whether 21st Century was in material breach of this CIA and, if so, whether:

 

a.                                      21st Century cured such breach within 30 days of its receipt of the Notice of Material Breach; or

 

32

 

b.                                      the alleged material breach could not have been cured within the 30 day period, but that, during the 30 day period following 21st Century’s receipt of the Notice of Material Breach: (i) 21st Century had begun to take action to cure the material breach; (ii) 21st Century pursued such action with due diligence; and (iii) 21st Century provided to OIG a reasonable timetable for curing the material breach.

 

For purposes of the exclusion herein, exclusion shall take effect only after an ALJ decision favorable to OIG, or, if the ALJ rules for 21st Century, only after a DAB decision in favor of OIG. 21st Century’s election of its contractual right to appeal to the DAB shall not abrogate OIG’s authority to exclude 21st Century upon the issuance of an ALJ’s decision in favor of OIG. If the ALJ sustains the determination of OIG and determines that exclusion is authorized, such exclusion shall take effect 20 days after the ALJ issues such a decision, notwithstanding that 21st Century may request review of the ALJ decision by the DAB. If the DAB finds in favor of OIG after an ALJ decision adverse to OIG, the exclusion shall take effect 20 days after the DAB decision. 21st Century shall waive its right to any notice of such an exclusion if a decision upholding the exclusion is rendered by the ALJ or DAB. If the DAB finds in favor of 21st Century, 21st Century shall be reinstated effective on the date of the original exclusion.

 

4.                                      Finality of Decision. The review by an ALJ or DAB provided for above shall not be considered to be an appeal right arising under any statutes or regulations. Consequently, the parties to this CIA agree that the DAB’s decision (or the ALJ’s decision if not appealed) shall be considered final for all purposes under this CIA.

 

XI.                              EFFECTIVE AND BINDING AGREEMENT

 

21st Century and OIG agree as follows:

 

A.                                    This CIA shall become final and binding on the date the final signature is obtained on the CIA.

 

B.                                    This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA.

 

33

 

C.                                    OIG may agree to a suspension of 21st Century’s obligations under this CIA based on a certification by 21st Century that it is no longer providing health care items or services that will be billed to any Federal health care program and it does not have any ownership or control interest, as defined in 42 U.S.C. §1320a-3, in any entity that bills any Federal health care program. If 21st Century is relieved of its CIA obligations, 21st Century shall be required to notify OIG in writing at least 30 days in advance if 21st Century plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the CIA will be reactivated or modified.

 

D.                                    All requirements and remedies set forth in this CIA are in addition to and do not affect (1) 21st Century’s responsibility to follow all applicable Federal health care program requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements.

 

E.                                     The undersigned 21st Century signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacities and that they are authorized to execute this CIA.

 

F.                                      This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA.

 

34

 

ON BEHALF OF 21ST CENTURY

 

 

	
/s/ Daniel E. Dosoretz,   MD
    	
 
    	
12/16/15
    
	
DANIEL E.   DOSORETZ, MD
    	
 
    	
DATE
    
	
Chief Executive   Officer
    	
 
    	
 
    
	
21st Century   Oncology, LLC
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/ Amy O.   Garrigues
    	
 
    	
12/15/2015
    
	
AMY O. GARRIGUES
    	
 
    	
DATE
    
	
K&L Gates   LLP
    	
 
    	
 
    
	
Counsel for 21st   Century Oncology, LLC
    	
 
    	
 
    

 

35

 

ON BEHALF OF THE OFFICE OF INSPECTOR GENERAL

OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES

 

 

	
/s/ Robert K. Deconti
    	
 
    	
12/16/15
    
	
ROBERT K.   DECONTI
    	
 
    	
DATE
    
	
Assistant Inspector   General for Legal Affairs
    	
 
    	
 
    
	
Office of   Inspector General
    	
 
    	
 
    
	
U. S. Department   of Health and Human Services
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/ Felicia E. Heimer
    	
 
    	
12/16/15
    
	
FELICIA E.   HEIMER
    	
 
    	
DATE
    
	
Senior Counsel
    	
 
    	
 
    
	
Office of   Inspector General
    	
 
    	
 
    
	
U. S. Department   of Health and Human Services
    	
 
    	
 
    

 

36

 

APPENDIX A

 

INDEPENDENT REVIEW ORGANIZATION

 

This Appendix contains the requirements relating to the Independent Review Organization (IRO) required by Section III.D of the CIA.

 

A.                                    IRO Engagement

 

1.                                      21st Century shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph D. Within 30 days after OIG receives the information identified in Section V.A.8 of the CIA or any additional information submitted by 21st Century in response to a request by OIG, whichever is later, OIG will notify 21st Century if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, 21st Century may continue to engage the IRO.

 

2.                                      If 21st Century engages a new IRO during the term of the CIA, that IRO must also meet the requirements of this Appendix. If a new IRO is engaged, 21st Century shall submit the information identified in Section V.A.8 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by 21st Century at the request of OIG, whichever is later, OIG will notify 21st Century if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, 21st Century may continue to engage the IRO.

 

B.                                    IRO Qualifications

 

The IRO shall:

 

1.                                      assign individuals to conduct the Claims Review who have expertise in the billing, coding, claims submission and other applicable Medicare and TRICARE program requirements;

 

2.                                      assign individuals who have expertise in determining the medical necessity of items and services pursuant to applicable Medicare and TRICARE requirements;

 

3.                                      assign individuals to design and select the Claims Review sample who are knowledgeable about the appropriate statistical sampling techniques;

 

37

 

4.                                      assign individuals to conduct the coding review portions of the Claims Review who have a nationally recognized coding certification and who have maintained this certification (e.g., completed applicable continuing education requirements); and

 

5.                                      have sufficient staff and resources to conduct the reviews required by the CIA on a timely basis.

 

C.                                    IRO Responsibilities

 

The IRO shall:

 

1.                                      perform each Claims Review in accordance with the specific requirements of the CIA;

 

2.                                      follow all applicable Medicare and TRICARE rules and reimbursement guidelines in making assessments in the Claims Review;

 

3.                                      request clarification from the appropriate authority (e.g., Medicare contractor), if in doubt of the application of a particular Medicare or TRICARE policy or regulation;

 

4.                                      respond to all OIG inquires in a prompt, objective, and factual manner; and

 

5.                                      prepare timely, clear, well-written reports that include all the information required by Appendix B to the CIA.

 

D.                                    IRO Independence and Objectivity

 

The IRO must perform the Claims Review in a professionally independent and objective fashion, as defined in the most recent Government Auditing Standards issued by the U.S. Government Accountability Office.

 

38

 

E.                                     IRO Removal/Termination

 

1.                                      21st Century and IRO. If 21st Century terminates its IRO or if the IRO withdraws from the engagement during the term of the CIA, 21st Century must submit a notice explaining (a) its reasons for termination of the IRO or (b) the IRO’s reasons for its withdrawal to OIG, no later than 30 days after termination or withdrawal. 21st Century must engage a new IRO in accordance with Paragraph A of this Appendix and within 60 days of termination or withdrawal of the IRO.

 

2.                                      OIG Removal of IRO. In the event OIG has reason to believe the IRO does not possess the qualifications described in Paragraph B, is not independent and objective as set forth in Paragraph D, or has failed to carry out its responsibilities as described in Paragraph C, OIG shall notify 21st Century in writing regarding OIG’s basis for determining that the IRO has not met the requirements of this Appendix. 21st Century shall have 30 days from the date of OIG’s written notice to provide information regarding the IRO’s qualifications, independence or performance of its responsibilities in order to resolve the concerns identified by OIG. If, following OIG’s review of any information provided by 21st Century regarding the IRO, OIG determines that the IRO has not met the requirements of this Appendix, OIG shall notify 21st Century in writing that 21st Century shall be required to engage a new IRO in accordance with Paragraph A of this Appendix. 21st Century must engage a new IRO within 60 days of its receipt of OIG’s written notice. The final determination as to whether or not to require 21st Century to engage a new IRO shall be made at the sole discretion of OIG.

 

39

 

APPENDIX B

 

CLAIMS REVIEW

 

A.                                    Claims Review. The IRO shall perform the Claims Review annually to cover each of the five Reporting Periods. The IRO shall perform all components of each Claims Review.

 

1.                                      Definitions. For the purposes of the Claims Review, the following definitions shall be used:

 

a.                                      Overpayment: The amount of money 21st Century has received in excess of the amount due and payable under Medicare and TRICARE program requirements, as determined by the IRO in connection with the review of claims performed under this Appendix B, including any extrapolated Overpayments determined in accordance with Section A.3 of this Appendix B.

 

b.                                      Paid Claim: A claim submitted by 21st Century and for which 21st Century has received reimbursement from the Medicare and TRICARE programs.

 

c.                                       Population: The Population shall be defined as all Paid Claims during the 12-month period covered by the Claims Review.

 

d.                                      Error Rate: The Error Rate shall be the percentage of net Overpayments identified in the sample. The net Overpayments shall be calculated by subtracting all underpayments identified in the sample from all gross Overpayments identified in the sample. (Note: Any potential cost settlements or other supplemental payments should not be included in the net Overpayment calculation. Rather, only underpayments identified as part of the Discovery Sample shall be included as part of the net Overpayment calculation.)

 

The Error Rate is calculated by dividing the net Overpayment identified in the sample by the total dollar amount associated with the Paid Claims in the sample.

 

2.                                      Discovery Samples. The IRO shall randomly select and review two samples of 100 Paid Claims (Discovery Samples). One Discovery Sample is for Paid Claims drawn from all laboratory claims, and the other Discovery Sample is for Paid Claims drawn from all service lines within which physicians participate in 21st Century’s ancillary bonus pools. The Paid Claims shall be reviewed based on the supporting

 

 

documentation available at 21st Century’s office or under 21st Century’s control, and the applicable coverage, billing, coding, and medical necessity requirements, regulations, and/or guidance to determine whether the items and services provided were medically necessary, and whether the claims were correctly coded, submitted, and reimbursed.

 

If the Error Rate (as defined above) for each Discovery Sample is less than 5%, no additional sampling is required, nor is the Systems Review required. (Note: The guidelines listed above do not imply that this is an acceptable error rate. Accordingly, 21st Century should, as appropriate, further analyze any errors identified in the Discovery Sample. 21st Century recognizes that OIG or other HHS component, in its discretion and as authorized by statute, regulation, or other appropriate authority may also analyze or review Paid Claims included, or errors identified, in the Discovery Samples or any other segment of the universe.)

 

3.                                      Full Sample. If either Discovery Sample indicates that the Error Rate is 5% or greater, the IRO shall select an additional sample of Paid Claims (Full Sample) using commonly accepted sampling methods. The Paid Claims selected for the Full Sample shall be reviewed based on supporting documentation available at 21st Century or under 21st Century’s control and applicable billing and coding regulations and guidance to determine whether the items and services provided were medically necessary, and whether the claim was correctly coded, submitted, and reimbursed. For purposes of calculating the size of the Full Sample, the Discovery Sample may serve as the probe sample, if statistically appropriate. Additionally, the IRO may use the Paid Claims sampled as part of the Discovery Sample, and the corresponding findings for those Paid Claims, as part of its Full Sample, if: (1) statistically appropriate and (2) the IRO selects the Full Sample Paid Claims using the seed number generated by the Discovery Sample. The findings of the Full Sample shall be used by the IRO to estimate the actual Overpayment in the Population with a 90% confidence level and with a maximum relative precision of 25% of the point estimate. OIG, in its sole discretion, may refer the findings of the Full Sample (and any related workpapers) received from 21st Century to the appropriate Federal health care program payor (e.g., Medicare contractor), for appropriate follow-up by that payor.

 

4.                                      Systems Review. If either Discovery Sample identifies an Error Rate of 5% or greater, 21st Century’s IRO shall also conduct a Systems Review. The Systems Review shall consist of the following:

 

a.                                      a review of 21st Century’s medical necessity review process, and billing and coding systems and processes relating to claims submitted to Federal health care programs (including, but not limited to, the process by which the claims are reviewed for medical necessity, the operation of the billing system, the process by which claims are coded, safeguards to ensure proper coding, claims

 

 

submission and billing; and procedures to identify and correct inaccurate coding and billing);

 

b.                                      for each claim in the Discovery Samples and Full Samples that resulted in an Overpayment, the IRO shall review the system(s) and process(es) that generated the claim and identity any problems or weaknesses that may have resulted in the identified Overpayments, The IRO shall provide its observations and recommendations on suggested improvements to the system(s) and the process(es) that generated the claim.

 

5.                                      Other Requirements.

 

a.                                      Supplemental Materials. The IRO shall request all documentation and materials required for its review of the Paid Claims selected as part of the Discovery Samples or Full Samples (if applicable), and 21st Century shall furnish such documentation and materials to the IRO prior to the IRO initiating its review of the Discovery Samples or Full Samples (if applicable). If the IRO accepts any supplemental documentation or materials from 21st Century after the IRO has completed its initial review of the Discovery Samples or Full Samples (if applicable) (Supplemental Materials), the IRO shall identify in the Claims Review Report the Supplemental Materials, the date the Supplemental Materials were accepted, and the relative weight the IRO gave to the Supplemental Materials in its review. In addition, the IRO shall include a narrative in the Claims Review Report describing the process by which the Supplemental Materials were accepted and the IRO’s reasons for accepting the Supplemental Materials.

 

b.                                      Paid Claims without Supporting Documentation. Any Paid Claim for which 21st Century cannot produce documentation sufficient to support the Paid Claim shall be considered an error and the total reimbursement received by 21st Century for such Paid Claim shall be deemed an Overpayment. Replacement sampling for Paid Claims with missing documentation is not permitted.

 

c.                                       Use of First Samples Drawn. For the purposes of all samples (Discovery Sample(s) and Full Sample(s)) discussed in this Appendix, the Paid Claims selected in each first sample shall be used (i.e., it is not permissible to generate more than one list of random samples and then select one for use with the Discovery Sample or Full Sample).

 

 

6.                                      Repayment of Identified Overpayments. 21st Century shal1 repay within 30 days any Overpayment(s) identified in the Discovery Samples, regardless of the Error Rate, and (if applicable) the Full Samples, including any extrapolated Overpayments determined by the IRO in accordance with Section A.3 above, in accordance with payor refund policies. 21st Century shall make available to OIG all documentation that reflects the refund of the Overpayment(s) to the payor.

 

B.                                    Claims Review Report. The IRO shall prepare a Claims Review Report as described in this Appendix for each Claims Review performed. The following information shall be included in the Claims Review Report for each Discovery Sample and Full Sample (if applicable).

 

1.                                      Claims Review Methodology.

 

a.                                      Claims Review Population. A description of the Population subject to the Claims Review.

 

b.                                      Claims Review Objective. A clear statement of the objective intended to be achieved by the Claims Review.

 

c.                                       Source of Data. A description of the specific documentation relied upon by the IRO when performing the Claims Review (e.g., medical records, physician orders, certificates of medical necessity, requisition forms, local medical review policies (including title and policy number), CMS program memoranda (including title and issuance number), Medicare carrier or intermediary manual or bulletins (including issue and date), other policies, regulations, or directives).

 

d.                                      Review Protocol. A narrative description of how the Claims Review was conducted and what was evaluated.

 

e.                                       Supplemental Materials. A description of any Supplemental Materials as required by A.5.a., above.

 

2.                                      Statistical Sampling Documentation.

 

a.                                      A copy of the printout of the random numbers generated by the “Random Numbers” function of the statistical sampling software used by the IRO.

 

 

b.                                      A copy of the statistical software printout(s) estimating how many Paid Claims are to be included in the Full Sample, if applicable.

 

c.                                       A description or identification of the statistical sampling software package used to select the sample and determine the Full Sample size, if applicable.

 

3.                                      Claims Review Findings.

 

a.                                      Narrative Results.

 

i.              A description of 21st Century’s medical necessity review process, claims submission process, billing and coding system(s), including the identification, by position description, of the personnel involved in coding and billing.

 

ii.             A narrative explanation of the IRO’s findings and supporting rationale (including reasons for errors, patterns noted, etc.) regarding the Claims Review, including the results of each Discovery Sample, and the results of the Full Samples (if any).

 

b.                                      Quantitative Results.

 

i.              Total number and percentage of instances in which the IRO determined that the Paid Claims submitted by 21st Century (Claim Submitted) differed from what should have been the correct claim (Correct Claim), regardless of the effect on the payment.

 

ii.             Total number and percentage of instances in which the Claim Submitted differed from the Correct Claim and in which such difference resulted in an Overpayment to 21st Century.

 

iii.            Total dollar amount of all Overpayments in each Discovery Sample and Full Samples (if applicable).

 

iv.            Total dollar amount of Paid Claims included in each Discovery Sample and Full Sample, and the net Overpayment associated with the Discovery Samples and the Full Samples.

 

v.             Error Rate in each Discovery Sample and the Full Sample.

 

 

vi.                                   A spreadsheet of the Claims Review results that includes the following information for each Paid Claim: Federal health care program billed, beneficiary health insurance claim number, date of service, code submitted (e.g., DRG, CPT code, etc.), code reimbursed, allowed amount reimbursed by payor, correct code (as determined by the IRO), correct allowed amount (as determined by the IRO), dollar difference between allowed amount reimbursed by payor and the correct allowed amount.

 

vii.                                If a Full Sample is performed, the methodology used by the IRO to estimate the actual Overpayment in the Population and the amount of such Overpayment.

 

c.                                       Recommendations. The IRO’s report shall include any recommendations for improvements to 21st Century’s billing and coding system based on the findings of the Claims Review.

 

4.                                      Systems Review Findings. The IRO shall prepare a Systems Review Report based on the Systems Review performed (if applicable) that shall include the IRO’s observations, findings, and recommendations regarding:

 

a.                                      the strengths and weaknesses in 21st Century’s billing systems and processes;

 

b.                                      the strengths and weaknesses in 21st Century’s coding systems and processes;

 

c.                                       the strengths and weaknesses in 21st Century’s medical necessity review systems and processes; and

 

d.                                      possible improvements to 21st Century’s billing and coding systems and processes to address the specific problems or weaknesses that resulted in the identified Overpayments.

 

5.                                      Credentials. The names and credentials of the individuals who: (1) designed the statistical sampling procedures and the review methodology utilized for the Claims Review and (2) performed the Claims Review.EX-4.1

 Exhibit 4.1 

NUTANIX, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

This Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made and entered into as of August 26,
2014, by and among Nutanix, Inc., a Delaware corporation (the “Company”), the holders of outstanding shares of Common Stock of the Company listed on Schedule 1 hereto (the “Founders”), the purchasers of
Series E Preferred Stock of the Company listed on Schedule 2 hereto (the “New Investors”), and the holders of outstanding shares of Series A Preferred Stock of the Company, Series B Preferred Stock of the
Company, Series C Preferred Stock and Series D Preferred Stock of the Company listed on Schedule 3 hereto (the “Existing Preferred Holders” and, together with the New Investors, the “Investors”). 

RECITALS 
 A. The
Company, the Founders and the Existing Preferred Holders are parties to an Amended and Restated Investors’ Rights Agreement, dated as of December 11, 2013 (the “Prior Agreement”). 

B. The Company and certain New Investors have entered into a Series E Preferred Stock Purchase Agreement (the “Purchase
Agreement”) dated as of the date hereof, pursuant to which the Company desires to sell to the New Investors and the New Investors desire to purchase from the Company shares of the Company’s Series E Preferred Stock (the
“Series E Preferred Stock”). “Preferred Stock” means the Company’s Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E
Preferred Stock. A condition to the New Investors’ obligations under the Purchase Agreement is that the Company, the Founders, the Existing Preferred Holders and the New Investors enter into this Agreement in order to provide the Investors
(i) certain rights to register shares of the Company’s Common Stock (the “Common Stock”) issuable upon conversion of the Company’s Preferred Stock held by the Investors, (ii) certain rights to receive or inspect
information pertaining to the Company, and (iii) a right of first offer with respect to certain issuances by the Company of its securities. The Company, the Founders and the Existing Preferred Holders desire to induce the New Investors to
purchase shares of Series E Preferred Stock pursuant to the Purchase Agreement by agreeing to the terms and conditions set forth below. 

C. The Company, the Founders and the Existing Preferred Holders desire to amend and restate the Prior Agreement in its entirety as set forth
herein. 
 The parties agree as follows: 
  

	A.	Amendment of Prior Agreement; Waiver of Right of First Offer. 

 Pursuant to
Section 4.3 of the Prior Agreement, effective and contingent upon execution of this Agreement by the Company, Dheeraj Pandey and the requisite majority of the Existing Preferred Holders’ shares, the Prior Agreement is hereby amended and
restated in its entirety to read as set forth in this Agreement, and the Company, the Founders, the Existing Preferred Holders and the New Investors shall be bound by the provisions hereof as the sole agreement of the Company, the Founders, the
Existing Preferred Holders and the New Investors with respect to the subject matter hereof. The Existing Preferred Holders that are Major Investors (as that term is defined in the Prior Rights Agreement) hereby waive the right of first offer,
including the notice requirements, set forth in Section 2.3 of the Prior Agreement with respect to the issuance of Series E Preferred Stock. 

	1.	Registration Rights. 

 1.1 Definitions. For purposes of this
Section 1: 
 (a) The term “Exchange Act” means the Securities Exchange Act of 1934, as amended (and any successor
thereto) and the rules and regulations promulgated thereunder. 
 (b) The term
“Form S-3” means such form under the Securities Act as in effect on the date hereof or any successor form under the Securities Act that permits significant incorporation by reference of
the Company’s subsequent public filings under the Exchange Act. 
 (c) The term “Founders’ Stock” means the
shares of Common Stock issued to the Founders. 
 (d) The term “Holder” means any person owning or having the right to
acquire Registrable Securities or any assignee thereof in accordance with Section 1.12 of this Agreement. Notwithstanding the foregoing, each of Ajeet Singh and Mohit Aron shall be considered a “Holder” solely for the purposes of
Section 2.13 hereof. 
 (e) The term “Qualified IPO” means a “Qualified Offering” as defined in the
Company’s Amended and Restated Certificate of Incorporation (the “Restated Certificate”) as such Restated Certificate may be amended from time to time. 

(f) The terms “register,” “registered,” and “registration” refer to a registration effected
by preparing and filing a registration statement or similar document in compliance with the Securities Act, and the declaration or ordering of effectiveness of such registration statement or document. 

(g) The term “Registrable Securities” means (i) the shares of Common Stock issuable or issued upon conversion of the
Preferred Stock or the Warrant Stock, other than shares for which registration rights have terminated pursuant to Section 1.15 hereof, (ii) the shares of Founders’ Stock, provided, however, that for the purposes of
Section 1.2, 1.4 and 1.13 the Founders’ Stock shall not be deemed Registrable Securities and the Founders shall not be deemed Holders, and (iii) any other shares of Common Stock of the Company issued as (or issuable upon the
conversion or exercise of any warrant, right or other security which is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares listed in (i) and (ii); provided, however, that the
foregoing definition shall exclude in all cases any Registrable Securities sold by a person in a transaction in which such person’s rights under this Agreement are not assigned. Notwithstanding the foregoing, Common Stock or other securities
shall only be treated as Registrable Securities if and for so long as (A) they have not been sold to or through a broker or dealer or underwriter in a public distribution or a public securities transaction, (B) they have not been sold in a
transaction exempt from the registration and prospectus delivery requirements of the Securities Act under Section 4(1) thereof so that all transfer restrictions, and restrictive legends with respect thereto, if any, are removed upon the
consummation of such sale, or (C) they have been transferred in accordance with Section 1.12 of this Agreement. 
 (h) The number
of shares of “Registrable Securities then outstanding” shall be determined by the number of shares of Common Stock outstanding which are, and the number of shares of Common Stock issuable pursuant to then exercisable or convertible
securities which are Registrable Securities. 

  
 -2- 

 (i) The term “SEC” means the U.S. Securities and Exchange Commission. 

(j) The term “Securities Act” means the U.S. Securities Act of 1933, as amended (and any successor thereto) and the rules and
regulations promulgated thereunder. 
 (k) The term “Warrant Stock” means the (i) shares of Series A Preferred
Stock issuable upon exercise of those certain Warrants to Purchase Shares of Capital Stock issued pursuant to that certain Convertible Note and Warrant Purchase Agreement dated December 21, 2009, (ii) shares of Series D Preferred Stock
issuable upon exercise of that certain Warrant to Purchase Stock dated November 26, 2013, and (iii) shares of Series D Preferred Stock issuable upon exercise of that certain Plain English Warrant Agreement dated December 12, 2013.

 (l) The term “Wellington” shall mean Wellington Management Company, LLP, and any affiliated successor investment advisor
or subadvisor thereof to the Wellington Investors. 
 (m) The term “Wellington Investors” shall mean those Investors that
are advisory or subadvisory clients of Wellington. 
 1.2 Request for Registration. 

(a) If the Company shall receive at any time after the earlier of August 26, 2016 or six months after the effective date of the first
registration statement for a public offering of securities of the Company (other than a registration statement relating either to the sale of securities to employees of the Company pursuant to a stock option, stock purchase or similar plan or an SEC
Rule 145 transaction), a written request from the Holders of at least a majority of the Registrable Securities then outstanding or the Holders of at least a majority of the Series D Preferred Stock then outstanding that the Company file a
registration statement under the Securities Act covering the registration of at least such number of the Registrable Securities having an anticipated aggregate offering price, net of underwriting discounts and commissions, of at least $5,000,000,
then the Company shall, within 10 days of the receipt thereof, give written notice of such request to all Holders and shall, subject to the limitations of subsection 1.2(b), use its best efforts to file as soon as practicable, and in any event
within 90 days of the receipt of such request, a registration statement under the Securities Act covering all Registrable Securities which the Holders request to be registered within 20 days of the mailing of such notice by the Company. 

(b) If the Holders initiating the registration request hereunder (“Initiating Holders”) intend to distribute the Registrable
Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to this Section 1.2 and the Company shall include such information in the written notice referred to in
subsection 1.2(a). The underwriter will be selected by a majority in interest of the Initiating Holders and shall be reasonably acceptable to the Company. In such event, the right of any Holder to include its Registrable Securities in such
registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting (unless otherwise mutually agreed by a majority in interest of the
Initiating Holders and such Holder) to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided in subsection 1.5(e)) enter into an underwriting agreement
in customary form with the underwriter or underwriters selected for such underwriting. Notwithstanding any other provision of this Section 1.2, if the underwriter advises the Initiating Holders in writing that marketing factors require a
limitation of the number of shares to be 

  
 -3- 

 
underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that would otherwise be underwritten pursuant hereto, and the number of shares of Registrable
Securities that may be included in the underwriting shall be allocated among all participating Holders thereof, including the Initiating Holders, in proportion (as nearly as practicable) to the amount of Registrable Securities of the Company owned
by each participating Holder; provided, however, that the number of shares of Registrable Securities to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. 

(c) Notwithstanding the foregoing, if the Company shall furnish to Holders requesting a registration statement pursuant to this
Section 1.2, a certificate signed by the President of the Company stating that in the good faith judgment of the Board of Directors of the Company, it would be seriously detrimental to the Company and its holders of capital stock for such
registration statement to be filed and it is therefore essential to defer the filing of such registration statement, the Company shall have the right to defer such filing for a period of not more than 120 days after receipt of the request of the
Initiating Holders; provided, however, that the Company may not utilize this right more than once in any twelve-month period. 
 (d)
In addition, the Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to this Section 1.2: 

(i) with respect to registrations under this Section 1.2 other than those requested solely by holders of Series D Preferred Stock, after
the Company has effected two (2) such registrations pursuant to this Section 1.2 and such registrations have been declared or ordered effective; 

(ii) with respect to registrations under this Section 1.2 requested solely by holders of Series D Preferred Stock, after the Company has
effected two (2) such registrations pursuant to this Section 1.2 and such registrations have been declared or ordered effective; 

(iii) during the period starting with the date 90 days prior to the Company’s good faith estimate of the date of filing of, and ending
on a date 90 days after the effective date of, a registration subject to Section 1.3 unless such offering is the initial public offering of the Company’s securities, in which case, ending on a date 180 days after the effective date of such
registration subject to Section 1.3; provided, that the Company is actively employing in good faith all reasonable efforts to cause such registration statement to become effective; or 

(iv) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 1.4. 
 1.3 Company
Registration. If (but without any obligation to do so) the Company proposes to register (including for this purpose a registration effected by the Company for holders of capital stock other than the Holders) any of its stock under the
Securities Act in connection with the public offering of such securities solely for cash (other than a registration relating solely to the sale of securities to participants in a Company stock plan or a transaction covered by Rule 145 under the
Securities Act, a registration in which the only stock being registered is Common Stock issuable upon conversion of debt securities which are also being registered, or any registration on any form which does not include substantially the same
information as would be required to be included in a registration statement covering the sale of the Registrable Securities), the Company shall, at such time, promptly give each Holder written notice of such registration. Upon the written request of
each Holder given within 20 days after mailing of such notice by the Company in accordance with Section 4.4, the Company shall, subject to the cut back provisions of Section 1.8, cause to be registered under the Securities Act all of the
Registrable Securities that each such Holder has requested to be registered. 

  
 -4- 

 1.4 Form S-3 Registration. In case the
Company shall receive from any Holder or Holders a written request or requests that the Company effect a registration on Form S-3 and any related qualification or compliance with respect to all or a part
of the Registrable Securities owned by such Holder or Holders, the Company will: 
 (a) promptly give written notice of the proposed
registration, and any related qualification or compliance, to all other Holders; and 
 (b) as soon as practicable, effect such registration
and all such qualifications and compliances as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Holder’s or Holders’ Registrable Securities as are specified in such request,
together with all or such portion of the Registrable Securities of any other Holder or Holders joining in such request as are specified in a written request given within 15 days after receipt of such written notice from the Company; provided,
however, that the Company shall not be obligated to effect any such registration, qualification or compliance, pursuant to this Section 1.4: (i) if Form S-3 is not available for such
offering by the Holders; (ii) if the Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate
price to the public (net of any underwriters’ discounts or commissions) of less than $3,000,000; (iii) if the Company shall furnish to the Holders a certificate signed by the President of the Company stating that in the good faith judgment
of the Board of Directors of the Company, it would be seriously detrimental to the Company and its holders of capital stock for such Form S-3 registration to be effected at such time, in which event the
Company shall have the right to defer the filing of the Form S-3 registration statement for a period of not more than 120 days after receipt of the request of the Holder or Holders under this
Section 1.4; provided, however, that the Company shall not utilize this right more than once in any 12-month period; (iv) if the Company has, within the 12-month period preceding the date of such request, already effected two
registrations on Form S-3 for the Holders pursuant to this Section 1.4; (v) in any particular jurisdiction in which the Company would be required to qualify to do business or to execute a
general consent to service of process in effecting such registration, qualification or compliance; or (vi) during the period ending 120 days after the effective date of a registration statement subject to Section 1.3. 

(c) Subject to the foregoing, the Company shall file a registration statement covering the Registrable Securities and other securities so
requested to be registered as soon as practicable after receipt of the request or requests of the Holders. Registrations effected pursuant to this Section 1.4 shall not be counted as demands for registration or registrations effected pursuant
to Sections 1.2 or 1.3, respectively. 
 1.5 Obligations of the Company. Whenever required under this Section 1 to
effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
 (a) Prepare and file
with the SEC a registration statement with respect to such Registrable Securities and use its best efforts to cause such registration statement to become effective, and, upon the request of the Holders of a majority of the Registrable Securities
registered thereunder, keep such registration statement effective for up to 120 days, or until the distribution described in such registration statement is completed, if earlier. 

(b) Prepare and file with the SEC such amendments and supplements to such registration statement and the prospectus used in connection with
such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement for up to 120 days, or until the distribution described in
such registration statement is completed, if earlier. 

  
 -5- 

 (c) Furnish to the Holders such number of copies of a prospectus, including a preliminary
prospectus, in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them. 

(d) Use its best efforts to register and qualify the securities covered by such registration statement under such other securities or Blue Sky
laws of such jurisdictions as shall be reasonably requested by the Holders, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of
process in any such states or jurisdictions. 
 (e) In the event of any underwritten public offering, enter into and perform its obligations
under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering. Each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement. 

(f) Notify each Holder of Registrable Securities covered by such registration statement at any time when a prospectus relating thereto is
required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a
material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing, such obligation to continue for 120 days. 

(g) Cause all such Registrable Securities registered pursuant hereunder to be listed on each securities exchange on which similar securities
issued by the Company are then listed. 
 (h) Provide a transfer agent and registrar for all Registrable Securities registered pursuant
hereunder and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration. 

(i) Use its best efforts to furnish, at the request of any Holder requesting registration of Registrable Securities pursuant to this
Section 1, on the date that such Registrable Securities are delivered to the underwriters for sale in connection with a registration pursuant to this Section 1, if such securities are being sold through underwriters, (i) an opinion,
dated such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters and (ii) a letter
dated such date, from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the
underwriters. 
 1.6 Furnish Information. It shall be a condition precedent to the obligations of the Company to take any
action pursuant to this Section 1 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method
of disposition of such securities as shall be required to effect the registration of such Holder’s Registrable Securities. The Company shall have no obligation with respect to any registration requested pursuant to Section 1.2 or
Section 1.4 of this Agreement if, as a result of the application of the preceding sentence, the number of shares or the anticipated aggregate offering price of the Registrable Securities to be included in the registration does not equal or
exceed the number of shares or the anticipated aggregate offering price required to originally trigger the Company’s obligation to initiate such registration as specified in subsection 1.2(a) or subsection 1.4(b), whichever is applicable. 

  
 -6- 

 1.7 Expenses of Registration. 

(a) Demand Registration. All expenses (other than underwriting discounts and commissions) incurred in connection with
registrations, filings or qualifications pursuant to Section 1.2, including (without limitation) all registration, filing and qualification fees, printers’ and accounting fees, fees and disbursements of counsel for the Company, and the
reasonable fees and disbursements of one counsel for the selling Holders selected by them in an amount not to exceed $20,000, shall be borne by the Company; provided, however, that the Company shall not be required to pay for any expenses of
any registration proceeding begun pursuant to Section 1.2 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all participating Holders
shall bear such expenses pro rata on the basis of the number of Registrable Securities to be registered), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one demand registration pursuant to
Section 1.2; provided further, however, that if at the time of such withdrawal, the Holders (i) have learned of a material adverse change in the condition, business, or prospects of the Company that was not known to the Holders at
the time of their request and (ii) have withdrawn the request with reasonable promptness following disclosure by the Company of such material adverse change, then the Holders shall not be required to pay any of such expenses and shall not
forfeit their rights pursuant to Section 1.2. 
 (b) Company Registration. All expenses (other than underwriting
discounts and commissions) incurred in connection with registrations, filings or qualifications of Registrable Securities pursuant to Section 1.3 for each Holder (which right may be assigned as provided in Section 1.12), including (without
limitation) all registration, filing, and qualification fees, printers’ and accounting fees, fees and disbursements of counsel for the Company and the reasonable fees and disbursements of one counsel for the selling Holder or Holders selected
by them with the approval of the Company, which approval shall not be unreasonably withheld, in an amount not to exceed $20,000, shall be borne by the Company. 

(c) Registration on Form S-3. All expenses incurred in connection with a registration requested pursuant to
Section 1.4, including (without limitation) all registration, filing, qualification, printers’ and accounting fees and the reasonable fees and disbursements of one counsel for the selling Holder or Holders selected by them with the
approval of the Company, which approval shall not be unreasonably withheld, in an amount not to exceed $20,000, and counsel for the Company, and any underwriters’ discounts or commissions associated with Registrable Securities, shall be borne
by the Company. 
 1.8 Underwriting Requirements. In connection with any offering involving an underwriting of shares of the
Company’s capital stock, the Company shall not be required under Section 1.3 to include any of the Holders’ securities in such underwriting unless they accept the terms of the underwriting as agreed upon between the Company and the
underwriters selected by the Company (or by other persons entitled to select the underwriters), and then only in such quantity as the underwriters determine in their sole discretion in good faith will not jeopardize the success of the offering by
the Company. If the total amount of securities, including Registrable Securities, requested by holders of capital stock to be included in such offering exceeds the amount of securities sold other than by the Company that the underwriters determine
in their sole discretion in good faith is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters
determine in their sole discretion will not jeopardize the success of the offering, apportioned as follows: (i) first, pro rata among Registrable Securities, (ii) second, to other shares requested to be included by Major Investors (as
defined below) and (iii) third to other securities of the Company that are not Registrable Securities, but in no event shall (a) the amount of Registrable Securities of the selling Holders included in the offering be reduced below 33% of
the total amount of securities included in such offering, unless such offering is the initial public offering of the Company’s securities, in which case, the selling 

  
 -7- 

 
Holders may be excluded if the underwriters make the determination described above and no other security holder’s securities are included or (b) any securities held by a Founder be
included if any securities held by any selling Holder (other than Founders) are excluded. For purposes of the preceding parenthetical concerning apportionment, for any selling security holder which is a holder of Registrable Securities and which is
a partnership or corporation, the partners, retired partners and holders of capital stock of such holder, or the estates and family members of any such partners and retired partners and any trusts for the benefit of any of the foregoing persons
shall be deemed to be a single “selling security holder,” and any pro-rata reduction with respect to such “selling security holder” shall be based upon the aggregate amount of shares carrying registration rights owned by
all entities and individuals included in such “selling security holder,” as defined in this sentence. If any Holder disapproves of the terms of any such underwriting, such Holder may elect to withdraw therefrom by written notice to the
Company and the underwriter, delivered at least 10 business days prior to the effective date of the registration statement. Any Registrable Securities excluded or withdrawn from such underwriting shall be excluded and withdrawn from the
registration. For any Holder which is a partnership, limited liability company or corporation, the partners, retired partners, members, retired members and stockholders of such Holder, or the estates and family members of any such partners, retired
partners, members and retired members and any trusts for the benefit of any of the foregoing person shall be deemed to be a single “Holder,” and any pro rata reduction with respect to such “Holder” shall be based upon the
aggregate amount of shares carrying registration rights owned by all entities and individuals included in such “Holder,” as defined in this sentence. 

1.9 Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any
such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 1. 

1.10 Indemnification. In the event any Registrable Securities are included in a registration statement under this
Section 1: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each Holder, the partners, officers,
directors and security holders of each Holder, legal counsel and accountants for each Holder, any underwriter (as defined in the Securities Act) for such Holder and each person, if any, who controls such Holder or underwriter within the meaning of
the Securities Act or the Exchange Act, against any losses, claims, damages, or liabilities (joint or several) to which they may become subject under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims,
damages, or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively a “Violation”): (i) any untrue statement or alleged untrue statement
of a material fact contained in such registration statement, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto, (ii) the omission or alleged omission to state therein a material
fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any state securities law or any rule or
regulation promulgated under the Securities Act, the Exchange Act or any state securities law; and the Company will pay to each such Holder, underwriter or controlling person, as incurred, any legal or other expenses reasonably incurred by them in
connection with investigating or defending any such loss, claim, damage, liability, or action; provided, however, that the indemnity agreement contained in this subsection 1.10(a) shall not apply to amounts paid in settlement of any such
loss, claim, damage, liability, or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld), nor shall the Company be liable to any Holder, underwriter or controlling person for any
such loss, claim, damage, liability, or action to the extent that it arises out of or is based upon a Violation which occurs in reliance upon and in conformity with written information furnished expressly for use in connection with such registration
by any such Holder, underwriter or controlling person. 

  
 -8- 

 (b) To the extent permitted by law, each selling Holder will indemnify and hold harmless the
Company, each of its directors, each of its officers who has signed the registration statement, each person, if any, who controls the Company within the meaning of the Securities Act, any underwriter, any other Holder selling securities in such
registration statement and any controlling person of any such underwriter or other Holder, against any losses, claims, damages, or liabilities (joint or several) to which any of the foregoing persons may become subject, under the Securities Act, the
Exchange Act or other federal or state law, insofar as such losses, claims, damages, or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation
occurs in reliance upon and in conformity with written information furnished by such Holder expressly for use in connection with such registration; and each such Holder will pay, as incurred, any legal or other expenses reasonably incurred by any
person intended to be indemnified pursuant to this subsection 1.10(b), in connection with investigating or defending any such loss, claim, damage, liability, or action; provided, however, that the indemnity agreement contained in this
subsection 1.10(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; provided
that in no event shall the aggregate obligations under this subsection 1.10(b) and subsection 1.10(d) below exceed the net proceeds from the offering received by such Holder, except in the case of willful fraud by such Holder. 

(c) Promptly after receipt by an indemnified party under this Section 1.10 of notice of the commencement of any action (including any
governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 1.10, deliver to the indemnifying party a written notice of the commencement thereof and the
indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the
parties; provided, however, that an indemnified party (together with all other indemnified parties which may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the reasonable fees and
expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any
other party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if prejudicial to its ability to defend such action, shall
relieve such indemnifying party of any liability to the indemnified party under this Section 1.10, but the omission so to deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified
party otherwise than under this Section 1.10. 
 (d) If the indemnification provided for in this Section 1.10 is held by a court
of competent jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage or expense referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall
contribute to the amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the
indemnified party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage or expense as well as any other relevant equitable considerations; provided that in no event shall the
aggregate obligations of a Holder under Subsection 1.10(b) above and this Subsection 1.10(d) exceed the net proceeds from the offering received by such Holder, except in the case of willful fraud by such Holder. The relative fault of the
indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by
the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. 

  
 -9- 

 (e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and
contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control; provided that in
no event shall the indemnification obligations of a Holder pursuant to such underwriting agreement exceed the net proceeds from the applicable offering received by such Holder, except in the case of willful fraud by such Holder. 

(f) The obligations of the Company and Holders under this Section 1.10 shall survive the completion of any offering of Registrable
Securities in a registration statement under this Section 1, and otherwise. 
 1.11 Reports Under the Exchange Act. With
a view to making available to the Holders the benefits of Rule 144 promulgated under the Securities Act and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without
registration or pursuant to a registration on Form S-3, the Company agrees to: 
 (a) make and
keep adequate current public information available, as those terms are understood and defined in SEC Rule 144, at all times after 90 days after the effective date of the first registration statement filed by the Company for the offering of its
securities to the general public so long as the Company remains subject to the periodic reporting requirements under Sections 13 or 15(d) of the Exchange Act; 

(b) take such action, including the voluntary registration of its Common Stock under Section 12 of the Exchange Act, as is necessary to
enable the Holders to utilize Form S-3 for the sale of their Registrable Securities, such action to be taken as soon as practicable after the end of the fiscal year in which the first registration
statement filed by the Company for the offering of its securities to the general public is declared effective; 
 (c) file with the SEC in a
timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act; and 
 (d) furnish to
any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after 90 days after the
effective date of the first registration statement filed by the Company), the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be
resold pursuant to Form S-3 (at any time after it so qualifies), (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company,
and (iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC which permits the selling of any such securities without registration or pursuant to such form. 

1.12 Assignment of Registration Rights. The rights to cause the Company to register Registrable Securities pursuant to this
Section 1 may be assigned (but only with all related obligations) by a Holder to a transferee or assignee (a) of at least 50% of the transferring Holder’s aggregate Registrable Securities originally obtained from the Company (or if
the transferring Holder then owns less than 50% of such originally acquired securities, then all remaining Registrable Securities then held by the transferring Holder), (b) that is an Affiliate, subsidiary, parent, partner, limited partner,
retired partner, member, retired member or holder of capital stock of a Holder, (c) that is an affiliated fund or entity of the Holder, which means with respect to a limited liability company or a limited liability partnership, a fund or entity
managed by the same manager or managing member or general partner or management company or by an entity 

  
 -10- 

 
controlling, controlled by, or under common control with such manager or managing member or general partner or management company (such a fund or entity, an “Affiliated Fund”),
(d) who is a Holder’s child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law (such a relation, a Holder’s
“Immediate Family Member”, which term shall include adoptive relationships), or (e) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member, provided the Company is, within a
reasonable time after such transfer, furnished with written notice of the name and address of such transferee or assignee and the securities with respect to which such registration rights are being assigned; and provided, further, that such
assignment shall be effective only if the transferee agrees to be bound by this Agreement and immediately following such transfer the further disposition of such securities by the transferee or assignee is restricted under the Securities Act. For
the purposes of determining the number of shares of Registrable Securities held by a transferee or assignee, the holdings of transferees and assignees of (i) a partnership who are partners or retired partners of such partnership or (ii) a
limited liability company who are members or retired members of such limited liability company (including Immediate Family Members of such partners or members who acquire Registrable Securities by gift, will or intestate succession) shall be
aggregated together and with the partnership or limited liability company; provided that all assignees and transferees who would not qualify individually for assignment of registration rights shall have a single attorney-in-fact for the
purpose of exercising any rights, receiving notices or taking any action under Section 1. 
 1.13 Limitations on Subsequent
Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior written consent of the Holders of at least a majority of the outstanding Registrable Securities, other than as provided to additional
purchasers pursuant to Section 4.3, enter into any agreement with any holder or prospective holder of any securities of the Company which would allow such holder or prospective holder (a) to include such securities in any registration
filed under Section 1.2 hereof, unless under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the inclusion of such securities will not reduce the amount
of the Registrable Securities of the Holders which are included or (b) to make a demand registration which could result in such registration statement being declared effective prior to the earlier of either of the dates set forth in subsection
1.2(a) or within 120 days of the effective date of any registration effected pursuant to Section 1.2. 
 1.14 Lock-Up
Agreement. 
 (a) Lock-Up Period; Agreement. In connection with the initial public offering of the Company’s
securities and upon request of the Company or the underwriters managing such offering of the Company’s securities, Holder hereby agrees not to sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any
securities of the Company (other than those included in the registration) without the prior written consent of the Company or such underwriters, as the case may be, for such period of time (not to exceed 180 days) from the effective date of such
registration as may be requested by the Company or such managing underwriters and to execute an agreement reflecting the foregoing as may be requested by the underwriters at the time of the Company’s initial public offering. 

(b) Limitations. The obligations described in Section 1.14(a) shall apply only if all officers, directors and 1%
securityholders of the Company enter into similar agreements, and shall not apply to a registration relating solely to employee benefit plans, or to a registration relating solely to a transaction pursuant to Rule 145 under the Securities Act.
If the restrictions set forth in Section 1.14(a) are terminated or waived with respect to any Holder or any other person or entity subject to such restrictions, except for a person or entity who is not an officer or director of the Company and
holds less than 1% of the outstanding Common Stock, on a fully-diluted and as-converted basis, then the restrictions on each Holder shall be terminated or waived to the same extent. 

  
 -11- 

 (c) Stop-Transfer Instructions. In order to enforce the foregoing covenants, the
Company may impose stop-transfer instructions with respect to the securities of each Holder (and the securities of every other person subject to the restrictions in Section 1.14(a)). 

(d) Transferees Bound. Each Holder agrees that it will not transfer securities of the Company unless each transferee agrees in
writing to be bound by all of the provisions of this Section 1.14; provided that this Section 1.14(d) shall not apply to transfers pursuant to a registration statement or transfers after the 12-month anniversary of the effective
date of the Company’s initial registration statement subject to this Section 1.14. 
 (e) Exceptions. Except for the
restrictions and limitations applicable to the Registrable Securities set forth in this Section 1.14 above, none of the provisions in this Section 1.14 shall in any way limit The Goldman Sachs Group, Inc. or any of its Affiliates (as
defined below) (collectively, “GS”) from engaging in any brokerage, investment, advisory, financial advisory, anti-raid advisory, principaling, merger advisory, financing, asset management, trading, market making, arbitrage,
investment activity and other similar activities conducted in the ordinary course of their business. The Company acknowledges that the restrictions contained in this Section 1.14 shall not apply to the Common Stock or any securities convertible
into or exercisable or exchangeable for Common Stock acquired by GS or by Fidelity Management & Research Company (together with its Affiliates, “Fidelity”) or any Wellington Investor following the effective date of the
first registration statement of the Company covering Common Stock (or other securities) to be sold on behalf of the Company in its first firm commitment underwritten public offering of its Common Stock. 

1.15 Termination of Registration Rights. No Holder shall be entitled to exercise any right provided for in this Section 1
after the earlier of (a) five years following the consummation of a Qualified IPO, (b) such time after the expiration of the lock-up period described in Section 1.14(a) above as Rule 144 or another similar exemption under the
Securities Act is available for the sale of all of such Holder’s shares during a three-month period without registration or (c) upon termination of this Agreement, as provided in Section 3.1. 

 

	2.	Covenants of the Company. 

 2.1 Delivery of Financial Statements.
Upon the request by a Major Investor (as hereinafter defined), the Company shall deliver to each Major Investor (other than a Major Investor reasonably deemed by the Company to be a competitor of the Company): 

(a) as soon as practicable, but in any event within 150 days after the end of each fiscal year of the Company, an income statement for such
fiscal year, a balance sheet of the Company and statement of stockholders’ equity as of the end of such year, and a statement of cash flows for such year, such year-end financial reports to be in reasonable detail, prepared in accordance with
generally accepted accounting principles (“GAAP”), and audited and certified by an independent public accounting firm of nationally recognized standing selected by the Company; 

(b) as soon as practicable after the end of the first, second and third quarterly accounting periods in each fiscal year of the Company, but
in any event within 60 days after the end of each such period, an unaudited income statement for each such quarterly period, an unaudited balance sheet of the Company and an unaudited statement of stockholders’ equity as of the end of such
quarterly period, and a statement of cash flows for each such quarterly period, such financial reports to be in reasonable detail, prepared in accordance with GAAP; and 

  
 -12- 

 (c) as soon as practicable, but in any event 30 days prior to the end of each fiscal year, a
budget and business plan for the next fiscal year, with quarterly forward projections. 
 Notwithstanding anything else in this Section 2.1 to the
contrary, the Company may cease providing the information set forth in this Section 2.1 during the period starting with the date 60 days before the Company’s good-faith estimate of the date of filing of a registration statement if it
reasonably concludes it must do so to comply with the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Section 2.1 shall be reinstated at such time as the
Company is no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective. 
 2.2
Inspection. The Company shall permit each Major Investor (except for a Major Investor reasonably deemed by the Company to be a competitor of the Company), at such Major Investor’s expense, as applicable, to visit and inspect the
Company’s properties, to examine its books of account and records and to discuss the Company’s affairs, finances and accounts with its officers, all at such reasonable times as may be requested by the Major Investor; provided,
however, that the Company shall not be obligated pursuant to this Section 2.2 to provide access to any information which it reasonably considers to be privileged or a trade secret or similar confidential information. For purposes of
clarification, in no case shall (i) SAPV, (ii) Riverwood Capital Partners, L.P. (“Riverwood”), (iii) Morgan Stanley Expansion Capital LP or MS Expansion Capital Co-Investment Vehicle LP (together, “Morgan
Stanley”), (iv) Fidelity or (v) any Wellington Investor be deemed a competitor of the Company for purposes of this Section 2. 

2.3 Right of First Offer. Subject to the terms and conditions specified in this Section 2.3, the Company hereby grants to
each Major Investor a right of first offer with respect to future sales by the Company of its Shares (as hereinafter defined). For purposes of this Agreement, a “Major Investor” shall mean (i) any Holder other than the Founders
who holds at least 4,000,000 shares (subject to adjustment for stock splits, stock dividends, reclassifications or the like) of Registrable Securities, (ii) any Holder who then holds at least $5,000,000 of Series C Preferred Stock, Series D
Preferred Stock, or Series E Preferred Stock valued at the initial purchase price of such Series C Preferred Stock, Series D Preferred Stock, or Series E Preferred Stock, as applicable, or (iii) solely to the extent that GS continues to hold at
least 600,000 shares of Series C Preferred Stock of the Company (as adjusted for stock splits, stock dividends, reclassifications or the like), GS Direct, L.L.C.; provided, however that Ajeet Singh and Mohit Aron shall be considered a
“Major Investor” solely for the purposes of Section 2.1 above; and provided, further that, without limiting the foregoing, Fidelity and all Wellington Investors shall be considered “Major Investors” solely for the
purposes of Section 2.1(a) and Section 2.1(b) above. For purposes of this Section 2.3, the term “Major Investor” includes any general partners, managing members and affiliates of a person that is otherwise a Major Investor,
including Affiliated Funds. A Major Investor who chooses to exercise the right of first offer may designate as purchasers under such right itself or its partners or affiliates, including Affiliated Funds, in such proportions as it deems appropriate.
Each time the Company proposes to offer any shares of, or securities convertible into or exercisable for any shares of, any class of its capital stock (“Shares”), the Company shall first make an offering of such Shares to each Major
Investor in accordance with the following provisions: 
 (a) The Company shall deliver a notice (the “RFO Notice”) to the
Major Investors stating (i) its bona fide intention to offer such Shares, (ii) the number of such Shares to be offered, and (iii) the price and teams, if any, upon which it proposes to offer such Shares. 

(b) Within 15 calendar days after delivery of the RFO Notice, the Major Investor may elect to purchase or obtain, at the price and on the
terms specified in the RFO Notice, up to that portion of such Shares which equals the proportion that the number of shares of Common Stock issued and held, or issuable upon conversion and exercise of all convertible or exercisable securities then
held, by such Major 

  
 -13- 

 
Investor bears to the sum of (i) the total number of shares of Common Stock then outstanding (assuming full conversion and exercise of all convertible or exercisable securities) and
(ii) shares of Common Stock issuable to employees, consultants or directors pursuant to a stock option plan, restricted stock plan, or other stock plan approved by the Board of Directors. Such purchase shall be completed at the same closing as
that of any third party purchasers or at an additional closing thereunder. The Company shall promptly, in writing, inform each Major Investor that purchases all the shares available to it (each, a “Fully-Exercising Investor”) of any
other Major Investor’s failure to do likewise. During the 10-day period commencing after receipt of such information, each Fully-Exercising Investor shall be entitled to obtain that portion of the Shares for which Major Investors were entitled
to subscribe but which were not subscribed for by the Major Investors that is equal to the proportion that the number of shares of Common Stock issued and held, or issuable upon conversion and exercise of all convertible or exercisable securities
then held, by such Fully-Exercising Investor bears to the total number of shares of Common Stock then outstanding (assuming full conversion and exercise of all convertible or exercisable securities) issued and held, or issuable upon conversion of
the Preferred Stock then held, by all the Major Investors. For avoidance of doubt, if the rights under this Section 2.3 are waived in respect of the issuance of Shares for any Major Investors, then the Company shall not permit any Major
Investors to participate in the issuance of such Shares unless the Company first provides all other Major Investors with the same rights under this Section 2.3 to participate in such issuance of Shares. 

(c) The Company may, during the 15-day period following the expiration of the period provided in subsection 2.3(b) hereof, offer the remaining
unsubscribed portion of the Shares to any person or persons at a price not less than, and upon terms no more favorable to the offeree than those specified in the RFO Notice. If the Company does not enter into an agreement for the sale of the Shares
within such period, or if such agreement is not consummated within 60 days of the execution thereof, the right provided hereunder shall be deemed to be revived and such Shares shall not be offered unless first reoffered to the Major Investors in
accordance herewith. 
 (d) The right of first offer in this Section 2.3 shall not be applicable to the issuance of Exempted Securities
(as defined in the Restated Certificate) or the Series E Preferred Stock issued or issuable pursuant to the Purchase Agreement. 
 (e) In
addition to the foregoing, the right of first offer in this Section 2.3 shall not be applicable with respect to any Major Investor and any subsequent securities issuance, if (i) at the time of such subsequent securities issuance, the Major
Investor is not an “accredited investor,” as that term is then defined in Rule 501(a) under the Securities Act and (ii) such subsequent securities issuance is otherwise being offered only to accredited investors. 

2.4 Confidentiality. Each Investor shall keep confidential and shall not disclose, divulge or use for any purpose (other than to
monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s intention to file a registration statement), unless such confidential
information (a) is known or becomes known to the public in general (other than as a result of a breach of this Section 2.4 by such Investor), (b) is or has been independently developed or conceived by the Investor without use of the
Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company; provided, however,
that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company;
(ii) to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions of this Section 2.4; (iii) to any Affiliate, partner, member, stockholder, or
wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor informs such person that such information is confidential and directs such person 

  
 -14- 

 
to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, provided that the Investor promptly notifies the Company of such disclosure and takes
reasonable steps to minimize the extent of any such required disclosure. 
 Ajeet Singh and Mohit Aron shall keep confidential and shall not
disclose, divulge or use for any purpose (other than to monitor their holdings in the Company) any information received pursuant to Section 2.1 or any other confidential information obtained from the Company, provided that Ajeet Singh
and Mohit Aron may disclose confidential information to their attorneys, accountants, and other similar professionals on a need-to-know basis solely to the extent necessary to obtain their services in connection with monitoring their respective
holdings in the Company. 
 2.5 Vesting of Employee Stock. Unless otherwise approved by the Board of Directors of the Company,
all employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be required to execute restricted stock or option agreements, as
applicable, providing for vesting of 25% of the shares at the end of the initial 12-month period of continuous service or employment, with the remaining shares vesting in equal monthly installments over the following 36 months thereafter. With
respect to any shares of stock purchased by any such person, the Company’s repurchase option shall provide that upon such person’s termination of employment or service with the Company, with or without cause, the Company or its assignee
shall have the option to purchase at cost any unvested shares of stock held by such person. 
 2.6 Board Observer Rights. 

(a) As long as Lightspeed Venture Partners (“Lightspeed”) owns any shares of Series A Preferred Stock and is not
entitled to designate two (2) of the directors serving on the Board of Directors of the Company, the Company shall invite a representative of Lightspeed to attend all meetings of its Board of Directors in a nonvoting observer capacity and, in
this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors, if so requested; provided, however, that such representative shall agree to hold in confidence and
trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof
if access to such information or attendance at such meeting could result in disclosure of trade secrets or highly confidential information or in a conflict of interest or adversely affect the attorney-client privilege between the Company and its
counsel. 
 (b) As long as SAP Ventures Fund II, L.P. and/or its affiliates (“SAPV”) owns at least 50% of the Series D
Preferred stock initially purchased by SAPV, the Company shall invite a representative of SAPV to attend all meetings of its Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all
notices, minutes, consents, and other materials that it provides to its directors, if so requested; provided, however, that such representative shall agree to hold in confidence and trust all information so provided; and provided
further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could reasonably result in disclosure of
trade secrets or highly confidential information or in a conflict of interest or adversely affect the attorney-client privilege between the Company and its counsel. The Company shall reimburse the SAPV observer for all travel and out-of-pocket
expenses for attending meetings of the Board of Directors or other related Company activities. 
 2.7 Confidential Information and
Invention Assignment Agreements. The Company shall require each person currently employed, and to be employed after the date hereof, by the Company, shall execute and deliver a Confidential Information and Invention Assignment Agreement in a
form approved by the Board of Directors of the Company. 

  
 -15- 

 2.8 Certain Actions by the Company. The Company shall not take any of the following
actions without the prior consent of the Board of Directors of the Company (including the consent of at least one of the Preferred Directors (as defined in the Restated Certificate) for subsection (c) below): 

(a) incur indebtedness other than in the ordinary course of business, including without limitation, normal course trade debt; 

(b) enter into any material transaction with its affiliates which is not in the ordinary course of business; or 

(c) issue, after the date of the Initial Closing (as defined in the Purchase Agreement), additional shares of Common Stock (or options to
purchase Common Stock) to Ajeet Singh, Dheeraj Pandey or Mohit Aron. 
 2.9 Use of Name. 

(a) The Company agrees that it will not, without the prior written consent of GS, use in connection with any public announcement, posting of
information on a website or written news release, advertising, publicity or otherwise, the name of Goldman Sachs & Co. or any of its affiliates or any partner or employee thereof, nor represent, directly or indirectly, that any product or
service provided by the Company has been approved or endorsed by GS. Notwithstanding the foregoing, the Company may use and disclose the name of GS in disclosures required by law or regulation; provided, GS is given prior written notice of
such requirement and an opportunity to seek a protective order. The Company hereby grants to GS permission to use the Company’s name and logo in GS’ marketing materials. GS shall include a trademark attribution notice giving notice of the
Company’s ownership of its trademarks in the marketing materials in which the Company’s name and logo appear. 
 (b) The Company
agrees that it will not, without the prior written consent of the Morgan Stanley, use in connection with any public announcement, posting of information on a website or written news release, advertising, publicity or otherwise, the name of the
Morgan Stanley or any of its affiliates or any partner or employee thereof, nor represent, directly or indirectly, that any product or service provided by the Company has been approved or endorsed by the Morgan Stanley. Notwithstanding the
foregoing, the Company may use and disclose the name of the Morgan Stanley in disclosures required by law or regulation; provided, the Morgan Stanley is given prior written notice of such requirement and an opportunity to seek a protective
order. The Company hereby grants to the Morgan Stanley permission to use the Company’s name and logo in the Morgan Stanley’s marketing materials. The Morgan Stanley shall include a trademark attribution notice giving notice of the
Company’s ownership of its trademarks in the marketing materials in which the Company’s name and logo appear. 
 (c) The Company
agrees that it will not use the name of Riverwood or any of its affiliates without the prior written consent of Riverwood. The Company and Riverwood must jointly agree on the timing and content of any public disclosure relating to Riverwood’s
investment in the Company. 
 2.10 Restrictive Covenants. 

(a) The Company agrees not to require any Investor or any of their Affiliates to (i) send any business opportunities to the Company or
(ii) violate any client confidence. Notwithstanding anything to 

  
 -16- 

 
the contrary in any “Transaction Agreement” (as such term is defined in the Series E Preferred Stock Purchase Agreement, dated as of the date hereof, between the Company and the
other parties thereto), the Company agrees that any Investor may disclose any confidential information of the Company it receives if such disclosure is required by law, regulation or any regulatory or governmental authority or pursuant to the advice
of counsel if such disclosure is requested by any regulatory or governmental authority; provided, the Company is given, to the extent reasonably practicable and legally permitted, prior written notice of such requirement or request and an
opportunity to seek a protective order with respect thereto. 
 (b) Notwithstanding anything to the contrary in any Transaction Agreement,
none of the provisions herein or therein shall in any way limit any Investor or any of its Affiliates from engaging in any brokerage, investment advisory, financial advisory, anti-raid advisory, principaling, merger advisory, financing, asset
management, trading, market making, arbitrage, investment activity or other similar activities conducted in the ordinary course of its business. 

(c) The Company agrees that it will not enter into any agreement that contains a non-competition or non-solicitation covenant that binds any
Investor or any Affiliate of any Investor. 
 2.11 Information. The Company agrees to keep each of the Major Investors
reasonably informed, on a current basis, of all proceedings, notices or changes with respect to any criminal, material tax or material regulatory investigation or other criminal, material tax or material regulatory action involving the Company or
any of its subsidiaries, or, to the Company’s knowledge, its directors and officers. 
 2.12 Hart-Scott-Rodino Antitrust
Improvements Act. Any holders of Series E Preferred Stock who are required to make any filings or notifications under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection
with the acquisition of such shares of Series E Preferred Stock, shall have made such filings or notifications within 60 days of the date hereof. 

2.13 Termination of Certain Covenants. 

(a) Each of the covenants set forth in this Section 2 (other than the covenants set forth in Sections 2.4 and this 2.13) shall
terminate as to each Holder and be of no further force or effect (i) immediately prior to the consummation of a Qualified IPO or (ii) upon termination of this Agreement, as provided in Section 3.1. 

(b) The covenants set forth in Sections 2.1, 2.2 and 2.11 shall terminate as to each Holder and be of no further force or effect when the
Company first becomes subject to the periodic reporting requirements of Sections 13 or 15(d) of the Exchange Act, if this occurs earlier than the events described in Section 2.13(a). 

(c) The covenants set forth in Section 2.1 shall terminate as to Ajeet Singh and be of no further force or effect at such time as Ajeet
Singh holds fewer than 3,500,000 shares of Common Stock of the Company (as adjusted for stock splits, stock dividends, reclassifications or the like), provided, however, that shares of Common Stock transferred by Ajeet Singh to Ajeet
Singh’s Immediate Family (as defined in the Amended and Restated Right of First Refusal and Co-Sale Agreement among the Company, the Founders and the Investors named therein, dated as of the date hereof) or a trust for Ajeet Singh’s
benefit or the benefit of Ajeet Singh’s Immediate Family, whenever so transferred, shall be included in the number of shares held by Ajeet Singh for the purposes of this Section 2.13(c). 

(d) The covenants set forth in Section 2.1 shall terminate as to Mohit Aron and be of no further force or effect at such time as Mohit
Aron holds fewer than 2,762,268 shares of Common Stock of the 

  
 -17- 

 
Company (as adjusted for stock splits, stock dividends, reclassifications or the like), provided, however, that shares of Common Stock transferred by Mohit Aron to Mohit Aron’s
Immediate Family (as defined in the Amended and Restated Right of First Refusal and Co-Sale Agreement among the Company, the Founders and the Investors named therein, dated as of the date hereof) or a trust for Mohit Aron’s benefit or the
benefit of Mohit Aron’s Immediate Family, whenever so transferred, shall be included in the number of shares held by Mohit Aron for the purposes of this Section 2.13(d). 

 

	3.	Termination of Agreement. 

 3.1 Termination Events. This Agreement
shall terminate and have no further force or effect upon the earlier of: 
 (a) the liquidation, dissolution or indefinite cessation of the
business operations of the Company; or 
 (b) the consummation of a Liquidation Transaction (as defined in the Restated Certificate);
provided, that the covenants set forth in Section 2.1, 2.2 and 2.11 shall not terminate if, following, and as a result of, such Liquidation Transaction, Fidelity or any Wellington Investor holds equity in an entity that is not subject to
the periodic reporting requirements of Section 13 or 15(d) of the Exchange Act; provided, that each of Fidelity and each Wellington Investor agree to work in good faith with the acquiring entity regarding the scope of such rights
following a Liquidation Transaction. 
  

	4.	Miscellaneous. 

 4.1 Entire Agreement. This Agreement constitutes
the entire agreement between the parties hereto pertaining to the subject matter hereof, and supersedes any and all other written or oral agreements relating to the subject matter hereof existing between the parties hereto. 

4.2 Successors and Assigns; Third Party Beneficiaries. Except as otherwise provided in this Agreement, the terms and conditions
of this Agreement shall inure to the benefit of and be binding upon the respective successors, assigns and legal representatives of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the
parties hereto or their respective successors, assigns and legal representatives any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 

4.3 Amendments and Waivers. Any term of this Agreement may be amended or waived only with the written consent of (a) the
Company, (b) Dheeraj Pandey (or his successor, assign and legal representative), (c) the holders of at least a majority of the Company’s outstanding Preferred Stock (or their respective successors and assigns) (voting on an
as-converted to Common Stock basis) and (d) the holders of at least 66.7% of the Company’s outstanding Series D Preferred Stock (or their respective successors and assigns); provided that, (i) no such amendment shall materially
and adversely affect any Investor in a different and disproportionate manner relative to the other Investors unless such amendment is agreed to in writing by such adversely affected Investor; (ii) amendment of this Agreement to provide rights
similar to the rights herein to future investors will not require the separate written consent of the holders of the Company’s outstanding Series D Preferred Stock (so long as the existing rights of the holders of the Company’s outstanding
Series D Preferred Stock under this Agreement are not changed or altered to remove or extinguish such existing rights; provided, that the rights granted to future investors may be greater or different than the existing rights of the holders
of the Company’s outstanding Series D Preferred Stock hereunder), (iii) Section 2.2 may not be amended or waived without the written consent of Riverwood; (iv) Sections 2.2 and 2.6(b) may not be amended or waived without the
written consent of SAPV; (v) Section 2.6(a) may not be amended 

  
 -18- 

 
or waived without the written consent of Lightspeed, (vi) Section 2.2 may not be amended or waived without the written consent of Morgan Stanley; (vii) no amendment shall adversely
affect the holders of Series E Preferred Stock unless such amendment is agreed to in writing by the holders of at least 66.7% of the Company’s outstanding Series E Preferred Stock (or their respective successors and assigns) (for the avoidance
of doubt, an amendment hereto to provide rights similar to the rights herein to future investors will not alone be considered adverse to the holders of Series E Preferred Stock so long as the existing rights of the holders of the Company’s
outstanding Series E Preferred Stock under this Agreement are not changed or altered to remove or extinguish such existing rights; provided, that the rights granted to future investors may be greater or different than the existing rights of
the holders of the Company’s outstanding Series E Preferred Stock hereunder); (viii) no such amendment shall materially and adversely affect Ajeet Singh or Mohit Aron in a different and disproportionate manner relative to the other
Founders unless such amendment is agreed to in writing by Ajeet Singh or Mohit Aron, as applicable; (ix) the definition of “Affiliate” as it relates to a Wellington Investor may not be amended or waived without the prior written
consent of such Wellington Investor, and (x) the definitions of “Wellington” and “Wellington Investors” may not be amended, terminated or waived without the prior written consent of the Wellington Investors holding a
majority of the Registrable Securities then outstanding and held by the Wellington Investors. Any amendment or waiver effected in accordance with this Section 4.3 shall be binding upon the Company, the Founders, the Investors, and each of their
respective successors and assigns. Notwithstanding the foregoing, this Agreement may be amended with only the written consent of the Company for the sole purpose of including additional purchasers of Series E Preferred Stock pursuant to the Purchase
Agreement as “Investors” and any such Investor shall be deemed to be an “Investor” for all purposes. 

4.4 Notices. Any notice required or permitted by this Agreement shall be in writing and shall be deemed sufficient upon
delivery, when delivered personally or by overnight courier or sent by email or fax (upon customary confirmation of receipt), or forty-eight (48) hours after being deposited in the U.S. mail as certified or registered mail with postage prepaid,
addressed to the party to be notified at such party’s address, email or fax number as set forth on the signature page or on Schedule 1 or Schedule 2 hereto, or as subsequently modified by written notice. 

4.5 Aggregation of Stock. All shares of capital stock of the Company held or acquired by Affiliated entities or persons shall be
aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate. As used herein,
“Affiliate” means, with respect to any specified Investor, any other Investor who, directly or indirectly, controls, is controlled by or is under common control with such Investor, including, without limitation, any general partner,
managing member, officer or director of such Investor, or any venture capital fund now or hereafter existing which is controlled by one or more general partners or managing members of, or shares the same management company with, such Investor.
Notwithstanding the foregoing, for purposes of this Agreement, (a) each Wellington Investor shall be deemed to be an Affiliate of each other Wellington Investor, and (b) an entity that is an Affiliate of a Wellington Investor shall not be
deemed to be an Affiliate of any other Wellington Investor unless such entity is a Wellington Investor (and, for the avoidance of doubt, an Affiliate of such entity shall not be deemed an Affiliate of any Wellington Investor solely by virtue of
being an Affiliate of such entity). 
 4.6 Severability. If one or more provisions of this Agreement are held to be
unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (a) such provision shall be
excluded from this Agreement, (b) the balance of this Agreement shall be interpreted as if such provision were so excluded and (c) the balance of this Agreement shall be enforceable in accordance with its terms. 

  
 -19- 

 4.7 Governing Law. This Agreement and all acts and transactions pursuant hereto and
the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of California, without giving effect to principles of conflicts of law. 

4.8 Counterparts. This Agreement may be executed (manually or electronically) in two or more counterparts, each of which shall
be deemed an original and all of which together shall constitute one and the same instrument. 
 4.9 Titles and Subtitles. The
titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 

[Signature Pages Follow] 

  
 -20- 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	THE COMPANY:
	
	NUTANIX, INC.
		
	By:		 /s/ Duston Williams

	(Signature)
		
	Name:		Duston Williams
	Title:		Chief Financial Officer
		
	Address:		
	1740 Technology Drive, Suite 150
	San Jose, CA 95110

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT OF NUTANIX, INC. 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	THE FOUNDERS:
	
	DHEERAJ PANDEY
	
	 /s/ Dheeraj Pandey

	(Signature)
		
	Address:		
	1740 Technology Drive, Suite 150
	San Jose, CA 95110
	
	THE PANDEY IRREVOCABLE DESCENDANTS’ TRUST
		
	By:		 /s/ Dheeraj Pandey

	Name:		Dheeraj Pandey
	Title:		Trustee
	
	 DHEERAJ PANDEY AND SWAPNA PANDEY,

TRUSTEES OF THE PANDEY REVOCABLE

TRUST

		
	By:		 /s/ Dheeraj Pandey

	Name:		Dheeraj Pandey
	Title:		Trustee

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT OF NUTANIX, INC. 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	THE FOUNDERS:
	
	AJEET SINGH
	
	 /s/ Ajeet Singh

	(Signature)
	
	SINGH/SAHARAN 2014 IRREVOCABLE DESCENDANTS’ TRUST
		
	By:		 /s/ Ajeet Singh

	Name:		Ajeet Singh
	Title:		Trustee
	
	SINGH/SAHARAN REVOCABLE TRUST DATED JANUARY 24, 2014, AJEET SINGH AND RENU SAHARAN TRUSTEES
		
	By:		 /s/ Ajeet Singh

	Name:		Ajeet Singh
	Title:		Trustee

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT OF NUTANIX, INC. 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	INVESTOR:
	
	Fidelity Securities Fund: Fidelity Blue Chip Growth Fund
		
	By:		 /s/ Stacie M. Smith

	Name:		Stacie Smith
	Title:		Deputy Treasurer
	
	INVESTOR:
	
	Fidelity Securities Fund: Fidelity Series Blue Chip Growth Fund
		
	By:		 /s/ Stacie M. Smith

	Name:		Stacie Smith
	Title:		Deputy Treasurer
	
	INVESTOR:
	
	Fidelity Mt. Vernon Street Trust: Fidelity Series Growth Company Fund
		
	By:		 /s/ Stacie M. Smith

	Name:		Stacie Smith
	Title:		Deputy Treasurer
	
	INVESTOR:
	
	Fidelity Group Trust for Employee Benefit Plans: Fidelity Growth Company Commingled Pool
		
	By:		Fidelity Management & Trust Co.
		
	By:		 /s/ Kenneth Robins

	Name:		Kenneth Robbins
	Title:		Authorized Signatory

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT OF NUTANIX, INC. 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	INVESTOR:
	
	Fidelity Mt. Vernon Street Trust: Fidelity Growth Company Fund
		
	By:		 /s/ Stacie M. Smith

	Name:		Stacie Smith
	Title:		Deputy Treasurer
	
	INVESTOR:
	
	Fidelity Securities Fund: Fidelity OTC Portfolio
		
	By:		 /s/ Stacie M. Smith

	Name:		Stacie Smith
	Title:		Deputy Treasurer
	
	INVESTOR:
	
	Fidelity Advisor Series VII: Fidelity Advisor Technology Fund
		
	By:		 /s/ Stacie M. Smith

	Name:		Stacie Smith
	Title:		Deputy Treasurer
	
	INVESTOR:
	
	Variable Insurance Products Fund IV: Technology Portfolio
		
	By:		 /s/ Stacie M. Smith

	Name:		Stacie Smith
	Title:		Deputy Treasurer

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT OF NUTANIX, INC. 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	INVESTOR:
	
	Fidelity Select Portfolios: Technology Portfolio
		
	By:		 /s/ Stacie M. Smith

	Name:		Stacie Smith
	Title:		Deputy Treasurer
	
	INVESTOR:
	
	Fidelity Central Investment Portfolios LLC: Fidelity Information Technology Central Fund
		
	By:		 /s/ Stacie M. Smith

	Name:		Stacie Smith
	Title:		Deputy Treasurer
	
	INVESTOR:
	
	Fidelity Magellan Fund: Fidelity Magellan Fund
		
	By:		 /s/ Stacie M. Smith

	Name:		Stacie Smith
	Title:		Deputy Treasurer
	
	INVESTOR:
	
	Fidelity Contrafund: Fidelity Contrafund
		
	By:		 /s/ Stacie M. Smith

	Name:		Stacie Smith
	Title:		Deputy Treasurer
	
	INVESTOR:
	
	Fidelity Contrafund: Fidelity Advisor Series Opportunistic Insights Fund
		
	By:		 /s/ Stacie M. Smith

	Name:		Stacie Smith
	Title:		Deputy Treasurer

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT OF NUTANIX, INC. 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	INVESTOR:
	
	Fidelity Group Trust for Employee Benefit Plans: Fidelity Contrafund Commingled Pool
		
	By:		Fidelity Management & Trust Co.
		
	By:		 /s/ Kenneth Robins

	Name:		Kenneth Robins
	Title:		Authorized Signatory
	
	INVESTOR:
	
	Fidelity Contrafund: Fidelity Advisor New Insights Fund
		
	By:		 /s/ Stacie M. Smith

	Name:		Stacie Smith
	Title:		Deputy Treasurer
	
	INVESTOR:
	
	Fidelity Contrafund: Fidelity Series Opportunistic Insights Fund
		
	By:		 /s/ Stacie M. Smith

	Name:		Stacie Smith
	Title:		Deputy Treasurer

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT OF NUTANIX, INC. 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	Alpha Opportunities Fund
		
	By:		 Wellington Management Company, LLP,
 as
investment adviser

		
	Name:		 /s/ Steven M. Hoffman

	Title:		Vice President and Counsel
	
	 Alpha Opportunities Fund
 c/o
Wellington Management Company, LLP

	280 Congress Street
	Boston, MA 02210
	
	With a copy to:
	
	WilmerHale
	60 State St.
	Boston, MA 02482
	
	Alpha Opportunities Trust
		
	By:		 Wellington Management Company, LLP,
 as
investment adviser

		
	Name:		 /s/ Steven M. Hoffman

	Title:		Vice President and Counsel
	
	 Alpha Opportunities Trust
 c/o
Wellington Management Company, LLP

	280 Congress Street
	Boston, MA 02210
	
	With a copy to:
	
	WilmerHale
	60 State St.
	Boston, MA 02482

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT OF NUTANIX, INC. 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	ConocoPhillips Retirement Plan
		
	By:		 Wellington Management Company, LLP,
 as
investment adviser

		
	Name:		 /s/ Steven M. Hoffman

	Title:		Vice President and Counsel
	
	 ConocoPhillips Retirement Plan
 c/o
Wellington Management Company, LLP

	280 Congress Street
	Boston, MA 02210
	
	With a copy to:
	
	WilmerHale
	60 State St.
	Boston, MA 02482
	
	Desjardins American Equity Growth Fund
		
	By:		 Wellington Management Company, LLP,
 as
investment adviser

		
	Name:		 /s/ Steven M. Hoffman

	Title:		Vice President and Counsel
	
	 Desjardins American Equity Growth Fund

c/o Wellington Management Company, LLP

	280 Congress Street
	Boston, MA 02210
	
	With a copy to:
	
	WilmerHale
	60 State St.
	Boston, MA 02482

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT OF NUTANIX, INC. 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	Global Multi-Strategy Fund
		
	By:		 Wellington Management Company, LLP,
 as
investment adviser

		
	Name:		 /s/ Steven M. Hoffman

	Title:		Vice President and Counsel
	
	 Global Multi-Strategy Fund
 c/o
Wellington Management Company, LLP

	280 Congress Street
	Boston, MA 02210
	
	With a copy to:
	
	WilmerHale
	60 State St.
	Boston, MA 02482
	
	Greatlink Global Technology Fund
		
	By:		 Wellington Management Company, LLP,
 as
investment adviser

		
	Name:		 /s/ Steven M. Hoffman

	Title:		Vice President and Counsel
	
	 Greatlink Global Technology Fund

c/o Wellington Management Company, LLP

	280 Congress Street
	Boston, MA 02210
	
	With a copy to:
	
	WilmerHale
	60 State St.
	Boston, MA 02482

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT OF NUTANIX, INC. 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	Hartford Global Capital Appreciation Fund
		
	By:		 Wellington Management Company, LLP,
 as
investment adviser

		
	Name:		 /s/ Steven M. Hoffman

	Title:		Vice President and Counsel
	
	 Hartford Global Capital Appreciation Fund

c/o Wellington Management Company, LLP

	280 Congress Street
	Boston, MA 02210
	
	With a copy to:
	
	WilmerHale
	60 State St.
	Boston, MA 02482
	
	Hartford Growth Opportunities HLS Fund
		
	By:		 Wellington Management Company, LLP,
 as
investment adviser

		
	Name:		 /s/ Steven M. Hoffman

	Title:		Vice President and Counsel
	
	 Hartford Growth Opportunities HLS Fund

c/o Wellington Management Company, LLP

	280 Congress Street
	Boston, MA 02210
	
	With a copy to:
	
	WilmerHale
	60 State St.
	Boston, MA 02482

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT OF NUTANIX, INC. 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	Hartford Small Company HLS Fund
		
	By:		 Wellington Management Company, LLP,
 as
investment adviser

		
	Name:		 /s/ Steven M. Hoffman

	Title:		Vice President and Counsel
	
	 Hartford Small Company HLS Fund
 c/o
Wellington Management Company, LLP

	280 Congress Street
	Boston, MA 02210
	
	With a copy to:
	
	WilmerHale
	60 State St.
	Boston, MA 02482
	
	Hazelbrook Investors (Bermuda) L.P.
		
	By:		 Wellington Management Company, LLP,
 as
investment adviser

		
	Name:		 /s/ Steven M. Hoffman

	Title:		Vice President and Counsel
	
	 Hazelbrook Investors (Bermuda) L.P.

c/o Wellington Management Company, LLP

	280 Congress Street
	Boston, MA 02210
	
	With a copy to:
	
	WilmerHale
	60 State St.
	Boston, MA 02482

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT OF NUTANIX, INC. 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

					
	Hazelbrook Partners, L.P.
		
	By:		 Wellington Management Company, LLP,

as investment adviser

		
	Name:		 /s/ Steven M. Hoffman

	Title:		Vice President and Counsel
	
	 Hazelbrook Partners, L.P.
 c/o
Wellington Management Company, LLP

	280 Congress Street
	Boston, MA 02210
	
	With a copy to:
	
	 WilmerHale
 60 State St.

Boston, MA 02482

	
	Ithan Creek Master Investors (Cayman) L.P.
		
	By:		 Wellington Management Company, LLP,

as investment adviser

		
	Name:		 /s/ Steven M. Hoffman

	Title:		Vice President and Counsel
	
	 Ithan Creek Master Investors (Cayman) L.P.

c/o Wellington Management Company, LLP
 280 Congress Street

Boston, MA 02210

	
	With a copy to:
	
	 WilmerHale
 60 State
St.
 Boston, MA 02482

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT OF NUTANIX, INC. 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

					
	John Hancock Funds II Small Cap Growth Fund
		
	By:		 Wellington Management Company, LLP,

as investment adviser

		
	Name:		 /s/ Steven M. Hoffman

	Title:		Vice President and Counsel
	
	 John Hancock Funds II Small Cap Growth Fund

c/o Wellington Management Company, LLP

	280 Congress Street
	Boston, MA 02210
	
	With a copy to:
	
	 WilmerHale
 60 State St.

Boston, MA 02482

	
	John Hancock Pension Plan
		
	By:		 Wellington Management Company, LLP,

as investment adviser

		
	Name:		 /s/ Steven M. Hoffman

	Title:		Vice President and Counsel
	
	 John Hancock Pension Plan

c/o Wellington Management Company, LLP
 280 Congress Street

Boston, MA 02210

	
	With a copy to:
	
	 WilmerHale
 60 State
St.
 Boston, MA 02482

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT OF NUTANIX, INC. 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

					
	John Hancock Variable Insurance Trust Small Cap Growth Trust
		
	By:		 Wellington Management Company, LLP,

as investment adviser

		
	Name:		 /s/ Steven M. Hoffman

	Title:		Vice President and Counsel
	
	 John Hancock Variable Insurance Trust Small Cap Growth Trust

c/o Wellington Management Company, LLP

	280 Congress Street
	Boston, MA 02210
	
	With a copy to:
	
	 WilmerHale
 60 State St.

Boston, MA 02482

	
	MassMutual Select Small Cap Growth Equity Fund
		
	By:		 Wellington Management Company, LLP,

as investment adviser

		
	Name:		 /s/ Steven M. Hoffman

	Title:		Vice President and Counsel
	
	 MassMutual Select Small Cap Growth Equity Fund

c/o Wellington Management Company, LLP
 280 Congress Street

Boston, MA 02210

	
	With a copy to:
	
	 WilmerHale
 60 State
St.
 Boston, MA 02482

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT OF NUTANIX, INC. 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

					
	Mid Cap Stock Fund
		
	By:		 Wellington Management Company, LLP,

as investment adviser

		
	Name:		 /s/ Steven M. Hoffman

	Title:		Vice President and Counsel
	
	 Mid Cap Stock Fund
 c/o Wellington
Management Company, LLP

	280 Congress Street
	Boston, MA 02210
	
	With a copy to:
	
	 WilmerHale
 60 State St.

Boston, MA 02482

	
	Mid Cap Stock Trust
		
	By:		 Wellington Management Company, LLP,

as investment adviser

		
	Name:		 /s/ Steven M. Hoffman

	Title:		Vice President and Counsel
	
	 Mid Cap Stock Trust
 c/o
Wellington Management Company, LLP
 280 Congress Street

Boston, MA 02210

	
	With a copy to:
	
	 WilmerHale
 60 State
St.
 Boston, MA 02482

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT OF NUTANIX, INC. 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

					
	MML Small Cap Growth Equity Fund
		
	By:		 Wellington Management Company, LLP,

as investment adviser

		
	Name:		 /s/ Steven M. Hoffman

	Title:		Vice President and Counsel
	
	 MML Small Cap Growth Equity Fund

c/o Wellington Management Company, LLP

	280 Congress Street
	Boston, MA 02210
	
	With a copy to:
	
	 WilmerHale
 60 State St.

Boston, MA 02482

	
	Northeast Utilities Service Company Master Trust
		
	By:		 Wellington Management Company, LLP,

as investment adviser

		
	Name:		 /s/ Steven M. Hoffman

	Title:		Vice President and Counsel
	
	 Northeast Utilities Service Company Master Trust

c/o Wellington Management Company, LLP
 280 Congress Street

Boston, MA 02210

	
	With a copy to:
	
	 WilmerHale
 60 State
St.
 Boston, MA 02482

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT OF NUTANIX, INC. 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

					
	Optimum Small-Mid Cap Growth Fund
		
	By:		 Wellington Management Company, LLP,

as investment adviser

		
	Name:		 /s/ Steven M. Hoffman

	Title:		Vice President and Counsel
	
	 Optimum Small-Mid Cap Growth Fund

c/o Wellington Management Company, LLP

	280 Congress Street
	Boston, MA 02210
	
	With a copy to:
	
	 WilmerHale
 60 State St.

Boston, MA 02482

	
	Science & Technology Fund
		
	By:		 Wellington Management Company, LLP,

as investment adviser

		
	Name:		 /s/ Steven M. Hoffman

	Title:		Vice President and Counsel
	
	 Science & Technology Fund

c/o Wellington Management Company, LLP
 280 Congress Street

Boston, MA 02210

	
	With a copy to:
	
	 WilmerHale
 60 State
St.
 Boston, MA 02482

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT OF NUTANIX, INC. 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

					
	The Hartford Capital Appreciation Fund
		
	By:		 Wellington Management Company, LLP,

as investment adviser

		
	Name:		 /s/ Steven M. Hoffman

	Title:		Vice President and Counsel
	
	 The Hartford Capital Appreciation Fund

c/o Wellington Management Company, LLP

	280 Congress Street
	Boston, MA 02210
	
	With a copy to:
	
	 WilmerHale
 60 State St.

Boston, MA 02482

	
	The Hartford Global All-Asset Fund
		
	By:		 Wellington Management Company, LLP,

as investment adviser

		
	Name:		 /s/ Steven M. Hoffman

	Title:		Vice President and Counsel
	
	 The Hartford Global All-Asset Fund

c/o Wellington Management Company, LLP
 280 Congress Street

Boston, MA 02210

	
	With a copy to:
	
	 WilmerHale
 60 State
St.
 Boston, MA 02482

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT OF NUTANIX, INC. 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

					
	The Hartford Growth Opportunities Fund
		
	By:		 Wellington Management Company, LLP,

as investment adviser

		
	Name:		 /s/ Steven M. Hoffman

	Title:		Vice President and Counsel
	
	 The Hartford Growth Opportunities Fund

c/o Wellington Management Company, LLP

	280 Congress Street
	Boston, MA 02210
	
	With a copy to:
	
	 WilmerHale
 60 State St.

Boston, MA 02482

	
	The Hartford Small Company Fund
		
	By:		 Wellington Management Company, LLP,

as investment adviser

		
	Name:		 /s/ Steven M. Hoffman

	Title:		Vice President and Counsel
	
	 The Hartford Small Company Fund

c/o Wellington Management Company, LLP
 280 Congress Street

Boston, MA 02210

	
	With a copy to:
	
	 WilmerHale
 60 State
St.
 Boston, MA 02482

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT OF NUTANIX, INC. 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

					
	Treasurer of the State of North Carolina Equity Investment Fund Pooled Trust
		
	By:		 Wellington Management Company, LLP,

as investment adviser

		
	Name:		 /s/ Steven M. Hoffman

	Title:		Vice President and Counsel
	
	 Treasurer of the State of North Carolina Equity Investment Fund Pooled Trust

c/o Wellington Management Company, LLP

	280 Congress Street
	Boston, MA 02210
	
	With a copy to:
	
	 WilmerHale
 60 State St.

Boston, MA 02482

	
	Trustees of Hamilton College
		
	By:		 Wellington Management Company, LLP,

as investment adviser

		
	Name:		 /s/ Steven M. Hoffman

	Title:		Vice President and Counsel
	
	 Trustees of Hamilton College

c/o Wellington Management Company, LLP
 280 Congress Street

Boston, MA 02210

	
	With a copy to:
	
	 WilmerHale
 60 State
St.
 Boston, MA 02482

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT OF NUTANIX, INC. 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

					
	USAA Science & Technology Fund
		
	By:		 Wellington Management Company, LLP,

as investment adviser

		
	Name:		 /s/ Steven M. Hoffman

	Title:		Vice President and Counsel
	
	 USAA Science & Technology Fund

c/o Wellington Management Company, LLP

	280 Congress Street
	Boston, MA 02210
	
	With a copy to:
	
	 WilmerHale
 60 State St.

Boston, MA 02482

	
	DELL PRODUCTS L.P.
		
	By:		 /s/ James R. Lussier

	Name:		James R. Lussier
	Title:		Managing Director, Dell Ventures
	
	 Address:
 One Dell Way,
RR1-33
 Round Rock, TX 78682-8033
 U.S.A.

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT OF NUTANIX, INC. 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

					
	 THE INVESTORS:
  

RIVERWOOD CAPITAL PARTNERS L.P.

		
	By:		Riverwood Capital L.P., its general partner
		
	By:		Riverwood Capital GP Ltd., its general partner
		
	By:		 /s/ Jeffrey Parks

			(Signature)
		
	Name:		Jeffrey Parks
	Title:		Managing Director
	
	RIVERWOOD CAPITAL PARTNERS (PARALLEL – A) L.P.
		
	By:		Riverwood Capital L.P., its general partner
		
	By:		Riverwood Capital GP Ltd., its general partner
		
	By:		 /s/ Jeffrey Parks

			(Signature)
	Name:		Jeffrey Parks
	Title:		Managing Director
	
	RIVERWOOD CAPITAL PARTNERS (PARALLEL – B) L.P.
		
	By:		Riverwood Capital L.P., its general partner
		
	By:		Riverwood Capital GP Ltd., its general partner
		
	By:		 /s/ Jeffrey Parks

			(Signature)
		
	Name:		Jeffrey Parks
	Title:		Managing Director
					
					

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT OF NUTANIX, INC. 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

					
	 THE INVESTORS:
  

SAP VENTURES FUND II, L. P.,
 a Delaware limited
partnership

		
	By:		 SAP Ventures (GPE) II, L.L.C.,
 a
Delaware limited liability company
 its general partner

		
	By:		 /s/ Nino Marakovic

			(Signature)
		
	Name:		Nino Marakovic
	Title:		Managing Director
		
	By:		 /s/ Jayendra Das

			(Signature)
		
	Name:		Jayendra Das
	Title:		Managing Director
	
	LIGHTSPEED VENTURE PARTNERS VIII, L.P.
		
	By:		 Lightspeed General Partner VIII, L.P.,

its general partner

		
	By:		Lightspeed Ultimate General Partner VIII, Ltd., its general partner
			
			By:		 /s/ Ravi Mhatre

			Name:		Ravi Mhatre
					Duly Authorized Signatory
	
	LIGHTSPEED VENTURE PARTNERS VII, L.P.
		
	By:		 Lightspeed General Partner VII, L.P.,

its general partner

		
	By:		Lightspeed Ultimate General Partner VII, Ltd., its general partner
			
			By:		 /s/ Ravi Mhatre

			Name:		Ravi Mhatre
					Duly Authorized Signatory

  
 SIGNATURE PAGE TO
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT OF NUTANIX, INC. 

 SCHEDULE 1 

FOUNDERS 
 Name and
Address 
 Dheeraj Pandey 

Mohit Aron 
 Ajeet Singh 

 SCHEDULE 2 

NEW INVESTORS 
  

	
	Name and Address
	
	 Fidelity Securities Fund: Fidelity Blue Chip Growth Fund

Nominee: Ball & Co fbo Fidelity Securities Fund: Fidelity Blue Chip Growth Fund

Ball & Co
 C/o Citibank N.A/Custody

	
	 Fidelity Securities Fund: Fidelity Series Blue Chip Growth Fund

Nominee: Wavechart & Co fbo Fidelity Securities Fund: Fidelity Series Blue Chip

Growth Fund
 State Street Bank & Trust

	
	 Fidelity Mt. Vernon Street Trust: Fidelity Series Growth Company Fund

Nominee: WAVELENGTH + CO fbo Fidelity Mt. Vernon Street Trust: Fidelity

Series Growth Company Fund
 State Street Bank & Trust

 
 Fidelity Group Trust for Employee Benefit Plans: Fidelity Growth Company

Commingled Pool
 Nominee: Mag & Co fbo Fidelity Growth
Company Commingled Pool
 Brown Brothers Harriman & Co.

	
	Name and Address
	
	 Fidelity Mt. Vernon Street Trust: Fidelity Growth Company Fund

Nominee: Ball & Co fbo Fidelity Mt. Vernon Street Trust: Fidelity Growth

Company Fund
 Ball & Co

C/o Citibank N.A/Custody

	
	 Fidelity Securities Fund: Fidelity OTC Portfolio

Nominee: Booth & Co fbo Fidelity Securities Fund: Fidelity OTC Portfolio

The Northern Trust Company

	
	 Fidelity Advisor Series VII: Fidelity Advisor Technology Fund

Nominee: M Gardiner & Co fbo Fidelity Advisor Series VII: Fidelity Advisor

Technology Fund
 M.Gardiner & Co

C/O JPMorgan Chase Bank, N.A

	
	Name and Address
	
	 Variable Insurance Products Fund IV: Technology Portfolio

Nominee: M Gardiner & Co fbo Variable Insurance Products Fund IV: Technology

Portfolio
 M.Gardiner & Co

C/O JPMorgan Chase Bank, N.A

	
	 Fidelity Select Portfolios: Technology Portfolio

Nominee: Mag & Co fbo Fidelity Select Portfolios: Technology Portfolio

Brown Brothers Harriman & Co.

	
	 Fidelity Central Investment Portfolios LLC: Fidelity Information Technology

Central Fund
 Nominee: M Gardiner & Co fbo Fidelity
Central Investment Portfolios LLC:
 Fidelity Information Technology Central Fund

M.Gardiner & Co
 C/O JPMorgan Chase Bank, N.A

 
 Fidelity Magellan Fund: Fidelity Magellan Fund

Nominee: SAILBOAT & CO. fbo Fidelity Magellan Fund: Fidelity Magellan Fund

Nominee: State Street Bank & Trust

	
	Name and Address
	
	 Fidelity Contrafund: Fidelity Contrafund

Nominee: Mag & Co fbo Fidelity Contrafund: Fidelity Contrafund

Brown Brothers Harriman & Co.

	
	 Fidelity Contrafund: Fidelity Advisor Series Opportunistic Insights Fund

Nominee: Mag & Co fbo Fidelity Contrafund: Fidelity Advisor Series

Opportunistic Insights Fund
 Brown Brothers Harriman &
Co.

	
	 Fidelity Group Trust for Employee Benefit Plans: Fidelity Contrafund

Commingled Pool
 Nominee: Mag & Co fbo Fidelity
Contrafund Commingled Pool
 Brown Brothers Harriman & Co.
  

Fidelity Contrafund: Fidelity Advisor New Insights Fund
 Nominee:
Mag & Co fbo Fidelity Contrafund: Fidelity Advisor New Insights Fund
 Brown Brothers Harriman &
Co.

	
	Name and Address
	
	 Fidelity Contrafund: Fidelity Series Opportunistic Insights Fund

Nominee: Mag & Co fbo Fidelity Contrafund: Fidelity Series Opportunistic Insights Fund

Brown Brothers Harriman & Co.

	
	 Alpha Opportunities Fund
 Nominee:
Snailmarker & Co.
 c/o Wellington Management Company, LLP

	
	 Alpha Opportunities Trust
 Nominee:
Snaildive & Co.
 c/o Wellington Management Company, LLP
  

ConocoPhillips Retirement Plan
 Nominee: Mac & Co.

c/o Wellington Management Company, LLP

	
	Name and Address
	
	 Desjardins American Equity Growth Fund
 Nominee:
Desjardins Trust
 c/o Wellington Management Company, LLP

	
	 Global Multi-Strategy Fund
 Nominee:
Hare & Co.
 c/o Wellington Management Company, LLP

	
	 Greatlink Global Technology Fund
 Nominee:
Hare & Co.
 c/o Wellington Management Company, LLP

	
	 Hartford Global Capital Appreciation Fund

Nominee: Cudd & Co.
 c/o Wellington Management Company,
LLP

	
	Name and Address
	
	 Hartford Growth Opportunities HLS Fund
 Nominee:
Cudd & Co.
 c/o Wellington Management Company, LLP

	
	 Hartford Small Company HLS Fund
 Nominee:
Cudd & Co.
 c/o Wellington Management Company, LLP

	
	 Hazelbrook Investors (Bermuda) L.P.
 c/o
Wellington Management Company, LLP

	
	 Hazelbrook Partners, L.P.
 c/o Wellington
Management Company, LLP
  
 Ithan Creek Master Investors (Cayman) L.P.

c/o Wellington Management Company, LLP

	
	Name and Address
	
	 John Hancock Funds II Small Cap Growth Fund

Nominee: Snailcreek & Co.
 c/o Wellington Management
Company, LLP

	
	 John Hancock Pension Plan
 Nominee:
Stormbeach & Co.
 c/o Wellington Management Company, LLP

	
	 John Hancock Variable Insurance Trust Small Cap Growth Trust

Nominee: Beachcraft & Co.
 c/o Wellington Management
Company, LLP
  
 MassMutual Select Small Cap Growth Equity Fund

Nominee: Aurora & Co.
 c/o Wellington Management Company,
LLP

	
	Name and Address
	
	 Mid Cap Stock Fund
 Nominee:
Snailreef & Co.
 c/o Wellington Management Company, LLP

	  
 Mid Cap Stock Trust

Nominee: Tunaship & Co.
 c/o Wellington Management
Company, LLP

	  
 MML Small Cap Growth Equity Fund

Nominee: Aurora & Co.
 c/o Wellington Management Company,
LLP

	  
 Northeast Utilities Service Company Master Trust

Nominee: Mac & Co.
 c/o Wellington Management Company,
LLP

	
	Name and Address
	
	 Optimum Small-Mid Cap Growth Fund
 Nominee: Mac
& Co.
 c/o Wellington Management Company, LLP

	  
 Science & Technology Fund

Nominee: Handrail & Co.
 c/o Wellington Management
Company, LLP

	  
 The Hartford Capital Appreciation Fund

Nominee: Cudd & Co.
 c/o Wellington Management Company,
LLP

	  
 The Hartford Global All-Asset Fund

Nominee: Cudd & Co.
 c/o Wellington Management Company,
LLP

	  
 The Hartford Growth Opportunities Fund

Nominee: Cudd & Co.
 c/o Wellington Management Company,
LLP

	
	Name and Address
	  
 The Hartford Small Company Fund

Nominee: Cudd & Co.
 c/o Wellington Management Company,
LLP

	  
 Treasurer of the State of North Carolina Equity Investment Fund Pooled
Trust
 Nominee: Mac & Co.
 c/o Wellington Management
Company, LLP

	  
 Trustees of Hamilton College

Nominee: Mac & Co.
 c/o Wellington Management Company,
LLP
  
 USAA Science & Technology Fund

Nominee: Windsail & Co.
 c/o Wellington Management
Company, LLP

	
	Name and Address
	  
 Dell Products L.P.

 SCHEDULE 3 

EXISTING INVESTORS 
  

	
	Name and Address
	
	 Riverwood Capital Partners L.P.

c/o Riverwood Capital Management

	
	 Riverwood Capital Partners (Parallel – A) L.P.

c/o Riverwood Capital Management

	
	 Riverwood Capital Partners (Parallel – B) L.P.

c/o Riverwood Capital Management

	
	 SAP Ventures Fund II, L.P.

	
	 Khosla Ventures IV (CF), LP

	
	 Khosla Ventures IV, L.P.

	
	 Lightspeed Venture Partners VIII, L.P.

	
	 Lightspeed Venture Partners VII, L.P.

	
	 Battery Ventures IX, L.P.

	
	Name and Address
	
	 Battery Investment Partners IX, LLC

	
	 Greenspring Global Partners V-A, L.P.

	
	 Greenspring Global Partners V-C, L.P.

	
	 Greenspring Opportunities II, L.P.

	
	 Greenspring Opportunities II-A, L.P.

	
	 Comerica Ventures Incorporated
 M/C
7578

	
	 TriplePoint Capital LLC

	
	 Morgan Stanley Expansion Capital LP

	
	 MS Expansion Capital Co-Investment Vehicle LP

	
	 GS Direct, L.L.C.

	
	Name and Address
	
	 Blumberg Capital II, L.P.

	
	 Philip Solomon Living Trust UAD 2/114/2006
 c/o
Palladio Beauty Group

	
	 Beechwood Ventures LLC

	
	 Regent International Fund LLC

	
	 Accelerator Venture Capital I, L.P.

	
	The Nishar Family Trust, dated October 8, 2008
	
	Leslie Enterprises LP
	
	KAAJ Ventures LLC
	
	 Orrick Investments 2011 LLC

	
	 Alice and Harold Yu Family Trust established July 16,

2009, Harold M. Yu and Alice C. Yu, as trustees

	
	 The Board of Trustees of the Leland Stanford Junior

University (SBST)
 Direct Investments

Stanford Management Company

 NUTANIX, INC. 

AMENDMENT TO INVESTOR AGREEMENTS 

THIS AMENDMENT TO INVESTOR AGREEMENTS (this “Amendment”) is made as of February 28, 2015, among Nutanix, Inc., a
Delaware corporation (the “Company”), Dheeraj Pandey (the “Founder”), and the holders of Preferred Stock set forth on the signature pages hereto (each, an “Investor” and together, the
“Investors”). 
 WHEREAS, the parties entered into that certain Amended and Restated Investors’ Rights Agreement,
dated as of August 26, 2014 (the “Rights Agreement”), that certain Amended and Restated Right of First Refusal and Co-Sale Agreement, dated as of August 26, 2014 (the “Co-Sale Agreement”), and that certain
Amended and Restated Voting Agreement, dated as of August 26, 2014 (the “Voting Agreement,” and together with the Rights Agreement and the Co-Sale Agreement, the “Investor Agreements”). 

WHEREAS, the Company, the Founder, the holders of at least a majority of the Company’s outstanding Preferred Stock (voting on an
as-converted to Common Stock basis), and the holders of at least 66.67% of the Company’s outstanding Series D Preferred Stock (the “Requisite Parties”) desire to amend the Investor Agreements as set forth in this Amendment.

 WHEREAS, (i) Section 4.3 of the Rights Agreement provides that the Rights Agreement may be amended with the written consent of
the Requisite Parties, (ii) Section 4.3 of the Co-Sale Agreement provides that the Co-Sale Agreement may be amended with the written consent of the Requisite Parties, and (iii) Section 5.3 of the Voting Agreement provides that
the Voting Agreement may be amended with the written consent of the Requisite Parties and Lightspeed Venture Partners. 
 NOW, THEREFORE, in
consideration of the mutual covenants and agreements contained herein, and with reference to the above recitals, the parties hereby agree as follows: 

1. Amendment to Section 1.1(a) of the Voting Agreement. Section 1.1(a) of the Voting Agreement is hereby amended and restated
in its entirety to read as follows: 
 “(a) With respect to the director to be elected solely by the holders of a
majority of the outstanding shares of Series A Preferred Stock, voting as a separate class, pursuant to Section B(6)(a) of Article IV of the Company’s Amended and Restated Certificate of Incorporation (the “Restated
Certificate”), for so long as Lightspeed Venture Partners (“Lightspeed”) continues to hold at least 12,000,000 shares of Series A Preferred Stock (as adjusted for stock splits, stock dividends, recapitalizations,
reclassifications, combinations and the like), one (1) member of the Board designated by Lightspeed, which designee shall initially be Ravi Mhatre;” 

2. Amendment to Section 1.1(d) of the Voting Agreement. Section 1.1(d) of the Voting Agreement is hereby amended and restated
in its entirety to read as follows: 
 “(d) With respect to the director to be elected solely by holders of a majority
of the outstanding shares of Common Stock, voting as a separate class, pursuant to Section B(6)(d) of Article IV of the Restated Certificate, one (1) member of the Board who shall be the Company’s Chief Executive Officer, which
designee shall initially be Dheeraj Pandey;” 

 3. Amendment to Section 1.1(e) of the Voting Agreement. Section 1.1(e) of the
Voting Agreement is hereby amended and restated in its entirety to read as follows: 
 “(e) With respect to the
directors to be elected by the holders of a majority of the outstanding shares of Common Stock and Preferred Stock, voting together as a single class on an as converted basis, pursuant to Section B(6)(e) of Article IV of the Restated
Certificate, three (3) members of the Board (the “Independent Directors”) who are Independent (as defined below) and are designated by both (1) Dheeraj Pandey, individually, and (2) a majority of the Preferred
Directors (as defined in the Restated Certificate), which designees shall initially be Mark Leslie, Michael Scarpelli and Bipul Sinha. For purposes of this Agreement, “Independent” means an individual not otherwise Related (as
defined below) to the Company or any Investor or Founder. For purposes of this Agreement, an individual, firm, corporation, partnership, association, limited liability company, trust or any other entity (collectively, a “Person”)
shall be deemed to be “Related” to another Person who, directly or indirectly, controls, is controlled by or is under common control with such Person, including, without limitation, any general partner, managing member, officer or
director of such Person or any venture capital fund now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company with, such Person; and” 

4. Amendment to Section 1.1 of the Voting Agreement. A new Section 1.1(f) shall be inserted in the Voting Agreement following
Section 1.1(e) and shall read as follows: 
 “(f) With respect to the Founder Director or Designee (as defined
below in Section 3.2), one (1) member of the Board who shall be Dheeraj Pandey or another person designated solely by Dheeraj Pandey.” 

5. Amendment to Section 2 of the Voting Agreement. Section 2 of the Voting Agreement is hereby amended and restated in its
entirety to read as follows: 
 “2 Drag-Along Rights. 

2.1 Common Holder Drag Along. In the event that (a) Dheeraj Pandey (the “Key Holder”),
(b) the holders of at least a majority of the outstanding shares of Preferred Stock, voting together as a single class (the “Requisite Holders”), and (c) the Board, approve a “Liquidation Transaction” (as defined
in the Restated Certificate) or a sale of all of the Drag Shares (as defined below) held by the Requisite Holders (each, a “Company Sale”), and provided that (1) the Company Sale does not treat Ajeet Singh or Mohit Aron in a
different and disproportionate manner relative to the Key Holder, and (2) the limited indemnity agreed to by the Company in the Company Sale does not exceed the actual proceeds from the Company Sale, (i) if the Company Sale is structured
as a merger or consolidation of the Company, or a sale of all or substantially all of the Company’s assets, Mr. Singh and Mr. Aron shall vote, or cause to be voted, all Shares owned by Mr. Singh and Mr. Aron, respectively,
or over which Mr. Singh and Mr. Aron have voting control, from time to time and at all times, in whatever manner as shall be necessary (1) to ensure that at each annual or special meeting of stockholders at which a vote regarding a
Company Sale is held or pursuant to any written consent of the stockholders regarding a Company Sale, Mr. Singh and Mr. Aron agree to be present, in person or by proxy, at all meetings for the vote thereon, (2) to vote all Shares for
and raise no objections to such Company Sale, and (3) to waive and refrain from exercising any dissenters rights, appraisal 

  
 2 

 
rights or similar rights in connection with such merger, consolidation or asset sale, or (ii) if the Company Sale is structured as a sale of the stock of the Company, Mr. Singh and
Mr. Aron shall agree to sell all Drag Shares which Mr. Singh and Mr. Aron own or over which Mr. Singh and Mr. Aron otherwise exercise dispositive authority on the terms and conditions approved by the Requisite Holders. As
used herein, “Drag Shares” means any securities of the Company, including, without limitation, all shares of Common Stock and Preferred Stock of the Company, by whatever name called, now owned or subsequently acquired by a
stockholder, however acquired, whether through stock splits, stock dividends, reclassifications, recapitalizations, similar events or otherwise. Mr. Singh and Mr. Aron shall take all necessary and desirable actions approved by the
Requisite Holders in connection with the consummation of the Company Sale, including the execution of such agreements and such instruments and other actions reasonably necessary to consummate the Company Sale and effectuate the allocation and
distribution of the aggregate consideration upon the Company Sale. 
 2.2 Key Holder Drag Along. On or after
February 28, 2017, in the event that the Requisite Holders approve a Company Sale, and provided that (1) Dheeraj Pandey is no longer a full-time employee of the Company, (2) the Company Sale does not treat Mr. Pandey in a
different and disproportionate manner relative to the other Founders, and (3) the limited indemnity agreed to by the Company in the Company Sale does not exceed the actual proceeds from the Company Sale, (i) if the Company Sale is
structured as a merger or consolidation of the Company, or a sale of all or substantially all of the Company’s assets, Mr. Pandey shall vote, or cause to be voted, all Shares owned by Mr. Pandey or over which Mr. Pandey has
voting control, from time to time and at all times, in whatever manner as shall be necessary (1) to ensure that at each annual or special meeting of stockholders at which a vote regarding a Company Sale is held or pursuant to any written
consent of the stockholders regarding a Company Sale, Mr. Pandey agrees to be present, in person or by proxy, at all meetings for the vote thereon, (2) to vote all Shares for and raise no objections to such Company Sale, and (3) to
waive and refrain from exercising any dissenters rights, appraisal rights or similar rights in connection with such merger, consolidation or asset sale, or (ii) if the Company Sale is structured as a sale of the stock of the Company,
Mr. Pandey shall agree to sell all Drag Shares which Mr. Pandey owns or over which Mr. Pandey otherwise exercises dispositive authority on the terms and conditions approved by the Requisite Holders.” 

6. Amendment to Section 3.2 of the Voting Agreement. Section 3.2 of the Voting Agreement is hereby amended and restated in
its entirety to read as follows: 
 “3.2 Change in Number of Directors. The Stockholders will not vote
their shares of capital stock of the Company (or any such shares held in trust over which they have voting power) for any amendment or change to the Restated Certificate or Bylaws providing for the election of more or less than seven
(7) directors; provided, however, that in the event that Dheeraj Pandey is no longer the Company’s Chief Executive Officer, each Stockholder shall promptly vote, or cause to be voted, all Shares owned by such Stockholder, or over
which such Stockholder has voting control, (a) to amend or amend and restate the Restated Certificate to increase the number of directors of the Company by one (1) director to eight (8) directors (such additional director, the
“Founder Director or Designee”) and to provide that the holders of a majority of outstanding shares of Common Stock and Preferred Stock, voting together as a single class on an as converted basis, shall be entitled to elect such
Founder Director or Designee, and (b) to ensure that such Founder Director or Designee be elected in the manner set forth in Section 1.1(f).” 

  
 3 

 7. Amendment to Section 5.3 of the Voting Agreement. Section 5.3 of the Voting
Agreement is hereby amended and restated in its entirety to read as follows: 
 “5.3 Amendments and
Waivers. Any term of this Agreement may be amended or waived only with the written consent of (a) the Company, (b) the holders of at least a majority of the Company’s outstanding Preferred Stock (or their respective successors
and assigns) (voting on an as-converted to Common Stock basis), and (c) the holders of at least 66.7% of the Company’s outstanding Series D Preferred Stock (or their respective successors and assigns); provided that, (i) no
such amendment shall materially and adversely affect any Investor in a different and disproportionate manner relative to the other Investors unless such amendment is agreed to in writing by such adversely affected Investor; (ii) amendment of
this Agreement to provide rights similar to the rights herein to future investors will not require the separate written consent of the holders of the Company’s outstanding Series D Preferred Stock (so long as the existing rights of the holders
of the Company’s outstanding Series D Preferred Stock under this Agreement are not changed or altered to remove or extinguish such existing rights; provided, that the rights granted to future investors may be greater or different than
the existing rights of the holders of the Company’s outstanding Series D Preferred Stock hereunder), (iii) no such amendment shall amend or waive Section 1.1(a) unless such amendment is agreed to in writing by Lightspeed; (iv) no
such amendment shall amend or waive Section 1.1(b) unless such amendment is agreed to in writing by Khosla Ventures; (v) no such amendment shall amend or waive Section 1.1(c) unless such amendment is agreed to in writing by Riverwood;
(vi) no such amendment shall amend or waive Section 1.1(f) or Section 3.2 unless such amendment is agreed to in writing by Dheeraj Pandey, (vii) Section 2 may not be amended to require any Investor to take actions regarding
their Shares without the prior written consent of such Investor; (viii) no amendment shall adversely affect the holders of Series E Preferred Stock unless such amendment is agreed to in writing by the holders of at least 66.7% of the
Company’s outstanding Series E Preferred Stock (or their respective successors and assigns) (for the avoidance of doubt, an amendment hereto to provide rights similar to the rights herein to future investors will not alone be considered adverse
to the holders of Series E Preferred Stock so long as the existing rights of the holders of the Company’s outstanding Series E Preferred Stock under this Agreement are not changed or altered to remove or extinguish such existing rights;
provided, that the rights granted to future investors may be greater or different than the existing rights of the holders of the Company’s outstanding Series E Preferred Stock hereunder); (ix) no such amendment shall materially and
adversely affect Dheeraj Pandey, Ajeet Singh or Mohit Aron in a different and disproportionate manner relative to the other Founders unless such amendment is agreed to in writing by such differently and disproportionately affected Founder, as
applicable; (x) the definition of “Affiliate” as it relates to a Wellington Investor (as defined below) may not be amended or waived without the prior written consent of such Wellington Investor and (xi) the definitions of
“Wellington” and “Wellington Investors” may not be amended, terminated or waived without the prior written consent of the Wellington Investors holding a majority of the Company’s outstanding Preferred Stock
then outstanding and held by the Wellington Investors. Any amendment or waiver effected in accordance with this Section 5.3 shall be binding upon the Company, the Founders, the Investors, and each of their respective successors and assigns.
Notwithstanding the foregoing, this 

  
 4 

 
Agreement may be amended with only the written consent of the Company for the sole purpose of including additional purchasers of Series E Preferred Stock pursuant to the Purchase Agreement as
“Investors” and any such Investor shall be deemed to be an “Investor” for all purposes.” 
 8. Amendment to
Section 4.3 of the Rights Agreement. Section 4.3 of the Rights Agreement is hereby amended and restated in its entirety to read as follows: 

“4.3 Amendments and Waivers. Any term of this Agreement may be amended or waived only with the written
consent of (a) the Company, (b) the holders of at least a majority of the Company’s outstanding Preferred Stock (or their respective successors and assigns) (voting on an as-converted to Common Stock basis) and (c) the holders of
at least 66.7% of the Company’s outstanding Series D Preferred Stock (or their respective successors and assigns); provided that, (i) no such amendment shall materially and adversely affect any Investor in a different and
disproportionate manner relative to the other Investors unless such amendment is agreed to in writing by such adversely affected Investor; (ii) amendment of this Agreement to provide rights similar to the rights herein to future investors will
not require the separate written consent of the holders of the Company’s outstanding Series D Preferred Stock (so long as the existing rights of the holders of the Company’s outstanding Series D Preferred Stock under this Agreement are not
changed or altered to remove or extinguish such existing rights; provided, that the rights granted to future investors may be greater or different than the existing rights of the holders of the Company’s outstanding Series D Preferred
Stock hereunder), (iii) Section 2.2 may not be amended or waived without the written consent of Riverwood; (iv) Sections 2.2 and 2.6(b) may not be amended or waived without the written consent of SAPV; (v) Section 2.6(a) may
not be amended or waived without the written consent of Lightspeed, (vi) Section 2.2 may not be amended or waived without the written consent of Morgan Stanley; (vii) no amendment shall adversely affect the holders of Series E
Preferred Stock unless such amendment is agreed to in writing by the holders of at least 66.7% of the Company’s outstanding Series E Preferred Stock (or their respective successors and assigns) (for the avoidance of doubt, an amendment hereto
to provide rights similar to the rights herein to future investors will not alone be considered adverse to the holders of Series E Preferred Stock so long as the existing rights of the holders of the Company’s outstanding Series E Preferred
Stock under this Agreement are not changed or altered to remove or extinguish such existing rights; provided, that the rights granted to future investors may be greater or different than the existing rights of the holders of the
Company’s outstanding Series E Preferred Stock hereunder); (viii) no such amendment shall materially and adversely affect Dheeraj Pandey, Ajeet Singh or Mohit Aron in a different and disproportionate manner relative to the other Founders
unless such amendment is agreed to in writing by such differently and disproportionately affected Founder, as applicable; (ix) the definition of “Affiliate” as it relates to a Wellington Investor may not be amended or waived without
the prior written consent of such Wellington Investor, and (x) the definitions of “Wellington” and “Wellington Investors” may not be amended, terminated or waived without the prior written consent of the Wellington Investors
holding a majority of the Registrable Securities then outstanding and held by the Wellington Investors. Any amendment or waiver effected in accordance with this Section 4.3 shall be binding upon the Company, the Founders, the Investors, and
each of their respective successors and assigns. Notwithstanding the foregoing, this Agreement may be amended with only the written consent of the Company for the sole purpose of including additional purchasers of Series E Preferred Stock pursuant
to the Purchase Agreement as “Investors” and any such Investor shall be deemed to be an “Investor” for all purposes.” 

  
 5 

 9. Amendment to Section 4.3 of the Co-Sale Agreement. Section 4.3 of the Rights
Agreement is hereby amended and restated in its entirety to read as follows: 
 “4.3 Amendments and
Waivers. Any term of this Agreement may be amended or waived only with the written consent of (a) the Company, (b) the holders of at least a majority of the Company’s outstanding Preferred Stock (or their respective successors
and assigns) (voting on an as-converted to Common Stock basis), and (c) the holders of at least 66.7% of the Company’s outstanding Series D Preferred Stock (or their respective successors and assigns); provided that, (i) no
such amendment shall materially and adversely affect any Investor in a different and disproportionate manner relative to the other Investors unless such amendment is agreed to in writing by such adversely affected Investor; (ii) amendment of
this Agreement to provide rights similar to the rights herein to future investors will not require the separate written consent of the holders of the Company’s outstanding Series D Preferred Stock (so long as the existing rights of the holders
of the Company’s outstanding Series D Preferred Stock under this Agreement are not changed or altered to remove or extinguish such existing rights; provided, that the rights granted to future investors may be greater or different than
the existing rights of the holders of the Company’s outstanding Series D Preferred Stock hereunder), (iii) no amendment shall adversely affect the holders of Series E Preferred Stock unless such amendment is agreed to in writing by the
holders of at least 66.7% of the Company’s outstanding Series E Preferred Stock (or their respective successors and assigns) (for the avoidance of doubt, an amendment hereto to provide rights similar to the rights herein to future investors
will not alone be considered adverse to the holders of Series E Preferred Stock so long as the existing rights of the holders of the Company’s outstanding Series E Preferred Stock under this Agreement are not changed or altered to remove or
extinguish such existing rights; provided, that the rights granted to future investors may be greater or different than the existing rights of the holders of the Company’s outstanding Series E Preferred Stock hereunder), (iv) no
such amendment shall materially and adversely affect Dheeraj Pandey, Ajeet Singh or Mohit Aron in a different and disproportionate manner relative to the other Founders unless such amendment is agreed to in writing by such differently and
disproportionately affected Founder, as applicable, (v) the definition of “Affiliate” as it relates to a Wellington Investor (as defined below) may not be amended or waived without the prior written consent of such Wellington
Investor, and (vi) the definitions of “Wellington” and “Wellington Investors” may not be amended, terminated or waived without the prior written consent of the Wellington Investors holding a majority of the
Company’s outstanding Preferred Stock then outstanding and held by the Wellington Investors. Any amendment or waiver effected in accordance with this Section 4.3 shall be binding upon the Company, the Founders, the Investors, and each of
their respective successors and assigns. Notwithstanding the foregoing, this Agreement may be amended with only the written consent of the Company for the sole purpose of including additional purchasers of Series E Preferred Stock pursuant to the
Purchase Agreement as “Investors” and any such Investor shall be deemed to be an “Investor” for all purposes.” 

10. Defined Terms. Unless otherwise defined herein, all capitalized terms shall have the meanings ascribed to such terms in the
Investor Agreements. 

  
 6 

 11. Governing Law. This Amendment shall be governed by the internal substantive laws but
not the choice of law rules of California. 
 12. Counterparts; Facsimile. This Amendment may be executed in any number of
counterparts, each of which when so executed and delivered will be deemed an original, and all of which together shall constitute one and the same agreement. This Amendment may be executed and delivered by facsimile and upon such delivery the
facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other party. 
 13.
Further Assurances. The parties agree to execute such further documents and instruments and to take such further actions as may be reasonably necessary to carry out the purposes and intent of this Amendment. 

14. Entire Agreement. The Rights Agreement, Co-Sale Agreement and Voting Agreement, all as amended hereby, constitute the full and
entire agreement between the parties with regard to the subjects hereof and may not be further amended or modified except in accordance with the provisions of such agreements. 

15. Continuing Effectiveness. Except as modified by this Amendment, the Rights Agreement, Co-Sale Agreement and Voting Agreement shall
remain in full force and effect and no party by virtue of entering into this Amendment is waiving any rights it has under the Rights Agreement, Co-Sale Agreement or Voting Agreement, and once this Amendment is executed by the parties hereto, all
references in the Rights Agreement, Co-Sale Agreement and Voting Agreement to “the Agreement” or “this Agreement,” as applicable, shall refer to the Rights Agreement, Co-Sale Agreement or Voting Agreement as modified by this
Amendment. 
 [Signature Pages Follow] 

  
 7 

 IN WITNESS WHEREOF, the parties have duly executed this Amendment as of the day and year first
set forth above. 
  

			
	THE COMPANY:
	
	NUTANIX, INC.
		
	By:	 	 /s/ Duston Williams

	(Signature)
	
	Name: Duston Williams
	Title: Chief Financial Officer
	
	 Address:
 1740 Technology Drive,
Suite 150

	San Jose, CA 95110

 [Signature Page to Amendment to Investor Agreements] 

 IN WITNESS WHEREOF, the parties have duly executed this Amendment as of the day and year first
set forth above. 
  

			
	THE FOUNDERS:
	
	DHEERAJ PANDEY
	
	 /s/ Dheeraj Pandey

	(Signature)
	
	Address:
	1740 Technology Drive, Suite 150
	San Jose, CA 95110
	  
 THE PANDEY IRREVOCABLE DESCENDANTS’
TRUST

		
	By:		 /s/ Dheeraj Pandey

	Name: Dheeraj Pandey
	Title: Trustee
	
	DHEERAJ PANDEY AND SWAPNA PANDEY, TRUSTEES OF THE PANDEY REVOCABLE TRUST
		
	By:		 /s/ Dheeraj Pandey

	Name: Dheeraj Pandey
	Title: Trustee
	
	 THE SWAPNA PANDEY 2014

IRREVOCABLE DESCENDANTS’ TRUST

		
	By:		 /s/ Dheeraj Pandey

	Name: Dheeraj Pandey
	Title: Trustee

 [Signature Page to Amendment to Investor Agreements] 

 IN WITNESS WHEREOF, the parties have duly executed this Amendment as of the day and year first
set forth above. 
  

			
	THE INVESTORS:
	
	RIVERWOOD CAPITAL PARTNERS L.P.
		
	By:		Riverwood Capital L.P., its general partner
	By:		Riverwood Capital GP Ltd., its general partner
		
	By:		 /s/ Jeffrey T. Parks

	(Signature)
		
	Name:		Jeffrey T. Parks
	Title:		Managing Director
	
	 RIVERWOOD CAPITAL PARTNERS

(PARALLEL – A) L.P.

		
	By:		Riverwood Capital L.P., its general partner
	By:		Riverwood Capital GP Ltd., its general partner
		
	By:		 /s/ Jeffrey T. Parks

	(Signature)
	
	Name: Jeffrey T. Parks
	Title: Managing Director
	
	RIVERWOOD CAPITAL PARTNERS (PARALLEL – B) L.P.
	  
 By:
		Riverwood Capital L.P., its general partner
	By:		Riverwood Capital GP Ltd., its general partner
		
	By:		 /s/ Jeffrey T. Parks

	(Signature)
	
	Name: Jeffrey T. Parks
	Title: Managing Director

 [Signature Page to Amendment to Investor Agreements] 

 IN WITNESS WHEREOF, the parties have duly executed this Amendment as of the day and year first
set forth above. 
  

			
	THE INVESTORS:
	
	 SAP VENTURES FUND II, L. P.,

a Delaware limited partnership

		
	By:	 	SAP Ventures (GPE) II, L.L.C.,
		 	a Delaware limited liability company its general partner
		
	By:	 	 /s/ Nino Marakovic

	(Signature)
		
	Name:	 	Nino Marakovic
	Title:	 	Managing Director
		
	By:	 	 /s/ Jayendra Das

	(Signature)
		
	Name:	 	Jayendra Das
	Title:	 	Managing Director
	
	KHOSLA VENTURES IV, LP
	
	 By: Khosla Ventures IV Associates, LLC,
  

a Delaware limited liability company
 and general partner of
Khosla Ventures IV, LP

		
	By:	 	 /s/ Tamara L. Tompkins

	(Signature)
	
	Name: Tamara L. Tompkins
	Title: General Counsel and CAO
	
	KHOSLA VENTURES IV (CF), LP
		
	By:	 	 /s/ Tamara L. Tompkins

	(Signature)
	
	Name: Tamara L. Tompkins
	Title: General Counsel and CAO

 [Signature Page to Amendment to Investor Agreements] 

 IN WITNESS WHEREOF, the parties have duly executed this Amendment as of the day and year first
set forth above. 
  

					
	THE INVESTORS:
	
	LIGHTSPEED VENTURE PARTNERS VIII, L.P.
		
	By:		Lightspeed General Partner VIII, L.P.,
			its general partner
		
	By:		 Lightspeed Ultimate General Partner VIII,

Ltd., its general partner

			
			By:		 /s/ Ravi Mhatre

			Name: Ravi Mhatre
			Duly Authorized Signatory
	
	LIGHTSPEED VENTURE PARTNERS VII, L.P.
		
	By:		Lightspeed General Partner VII, L.P.,
		
			its general partner
		
	By:		 Lightspeed Ultimate General Partner VII,

Ltd., its general partner

			
			By:		 /s/ Ravi Mhatre

			Name: Ravi Mhatre
			Duly Authorized Signatory

 [Signature Page to Amendment to Investor Agreements]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}]]